

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 August 2005 (25.08.2005)

PCT

(10) International Publication Number
WO 2005/077946 A1

(51) International Patent Classification⁷: **C07D 455/06**,
A61K 31/473, A61P 25/14

[GB/GB]; 20 Christchurch Road, Abington, Northampton,
Northamptonshire NN1 5LN (GB).

(21) International Application Number:
PCT/GB2005/000464

(74) Agent: **HUTCHINS, Michael, Richard**; M.R. Hutchins
& Co., 23 Mount Sion, Tunbridge Wells, Kent TN1 1TZ
(GB).

(22) International Filing Date: 11 February 2005 (11.02.2005)

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0403037.5 11 February 2004 (11.02.2004) GB
60/543,531 11 February 2004 (11.02.2004) US

(71) Applicants (for all designated States except US): **CAM-
BRIDGE LABORATORIES LIMITED** [GB/GB];
Deltic House, Kingfisher Way, Silverlink Business Park,
Wallsend, Tyne and Wear NE28 9NX (GB). **TRIDGETT,
Robert** [GB/GB]; Cambridge Laboratories Limited,
Deltic House, Kingfisher Way, Silverlink Business Park,
Wallsend, Tyne and Wear NE28 9NX (GB).

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CLARKE, Ian**
[GB/GB]; 67 Lloyd Road, Abington, Northampton,
Northamptonshire NN1 5JE (GB). **TURTLE, Robert**
[GB/GB]; 72 Petersham Close, Newport Pagnell, Buck-
inghamshire MK16 0JG (GB). **JOHNSTON, Grant**

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: DIHYDROTETRABENAZINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

(57) Abstract: The invention provides novel isomers of dihydrotetrabenazine, individual enantiomers and mixtures thereof wherein the dihydrotetrabenazine is a 3,11 b-cis- dihydrotetrabenazine. Also provided are methods for the preparation of the novel isomers, pharmaceutical compositions containing them and their use in treating hyperkinetic movement disorders such as Huntington's disease, hemiballismus, senile chorea, tic, tardive dyskinesia and Tourette's syndrome.

WO 2005/077946 A1

DIHYDROTETRABENAZINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

This invention relates to novel dihydrotetrabenazine isomers, pharmaceutical compositions containing them, processes for making them and their therapeutic uses.

5 **Background of the Invention**

Tetrabenazine (Chemical name: 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-one) has been in use as a pharmaceutical drug since the late 1950s. Initially used as an anti-psychotic, tetrabenazine is currently used for treating hyperkinetic movement disorders such as Huntington's
10 disease, hemiballismus, senile chorea, tic, tardive dyskinesia and Tourette's syndrome, see for example Jankovic *et al.*, *Am. J. Psychiatry*. (1999) Aug; 156(8):1279-81 and Jankovic *et al.*, *Neurology* (1997) Feb; 48(2):358-62.

The primary pharmacological action of tetrabenazine is to reduce the supply of monoamines (e.g. dopamine, serotonin, and norepinephrine) in the central nervous
15 system by inhibiting the human vesicular monoamine transporter isoform 2 (hVMAT2). The drug also blocks postsynaptic dopamine receptors.

Tetrabenazine is an effective and safe drug for the treatment of a variety of hyperkinetic movement disorders and, in contrast to typical neuroleptics, has not been demonstrated to cause tardive dyskinesia. Nevertheless, tetrabenazine does
20 exhibit a number of dose-related side effects including causing depression, parkinsonism, drowsiness, nervousness or anxiety, insomnia and, in rare cases, neuroleptic malignant syndrome.

The central effects of tetrabenazine closely resemble those of reserpine, but it differs from reserpine in that it lacks activity at the VMAT1 transporter. The lack
25 of activity at the VMAT1 transporter means that tetrabenazine has less peripheral activity than reserpine and consequently does not produce VMAT1-related side effects such as hypotension.

The chemical structure of tetrabenazine is as shown in Figure 1 below.





Figure 1- Structure of tetrabenazine

The compound has chiral centres at the 3 and 11b carbon atoms and hence can, theoretically, exist in a total of four isomeric forms, as shown in Figure 2.



5

Figure 2 – Possible tetrabenazine isomers

In Figure 2, the stereochemistry of each isomer is defined using the “R and S” nomenclature developed by Cahn, Ingold and Prelog, see *Advanced Organic Chemistry* by Jerry March, 4th Edition, John Wiley & Sons, New York, 1992, pages 109-114. In Figure 2 and elsewhere in this patent application, the designations “R” or “S” are given in the order of the position numbers of the carbon atoms. Thus, for example, *RS* is a shorthand notation for 3*R*,11*bS*. Similarly, when three chiral centres are present, as in the dihydrotetrabenazines described below, the designations “R” or “S” are listed in the order of the carbon atoms 2, 3 and 11b. Thus, the 2*S*,3*R*,11*bR* isomer is referred to in short hand form as *SRR* and so on.


15

Commercially available tetrabenazine is a racemic mixture of the *RR* and *SS* isomers and it would appear that the *RR* and *SS* isomers (hereinafter referred to individually or collectively as *trans*-tetrabenazine because the hydrogen atoms at

the 3 and 11b positions have a *trans* relative orientation) are the most thermodynamically stable isomers.

Tetrabenazine has somewhat poor and variable bioavailability. It is extensively metabolised by first-pass metabolism, and little or no unchanged tetrabenazine is typically detected in the urine. The major metabolite is dihydrotetrabenazine (Chemical name: 2-hydroxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-benzo(a)quinolizine) which is formed by reduction of the 2-keto group in tetrabenazine, and is believed to be primarily responsible for the activity of the drug (see Mehvar *et al.*, *Drug Metab. Disp.*, 15, 250-255 (1987) and *J. Pharm. Sci.*, 76, No.6, 461-465 (1987)).

Four dihydrotetrabenazine isomers have previously been identified and characterised, all of them being derived from the more stable *RR* and *SS* isomers of the parent tetrabenazine and having a *trans* relative orientation between the hydrogen atoms at the 3 and 11b positions) (see Kilbourn *et al.*, *Chirality*, 9:59-62 (1997) and Brossi *et al.*, *Helv. Chim. Acta.*, vol. XLI, No. 193, pp1793-1806 (1958)). The four isomers are (+)- α -dihydrotetrabenazine, (-)- α -dihydrotetrabenazine, (+)- β -dihydrotetrabenazine and (-)- β -dihydrotetrabenazine. The structures of the four known dihydrotetrabenazine isomers are considered to be as shown in Figure 3.



20 Figure 3 – Structures of known isomers of dihydrotetrabenazine

Kilbourn *et al.*, (see *Eur. J. Pharmacol.*, 278:249-252 (1995) and *Med. Chem. Res.*, 5:113-126 (1994)) investigated the specific binding of individual radio-labelled

dihydrotetrabenazine isomers in the conscious rat brain. They found that the (+)- α - ^{11}C dihydrotetrabenazine (2*R*,3*R*,11*bR*) isomer accumulated in regions of the brain associated with higher concentrations of the neuronal membrane dopamine transporter (DAT) and the vesicular monoamine transporter (VMAT2). However, 5 the essentially inactive (-)- α - ^{11}C dihydrotetrabenazine isomer was almost uniformly distributed in the brain, suggesting that specific binding to DAT and VMAT2 was not occurring. The *in vivo* studies correlated with *in vitro* studies which demonstrated that the (+)- α - ^{11}C dihydrotetrabenazine isomer exhibits a K_i for [^3H]methoxytetrabenazine >2000-fold higher than the K_i for the (-)- α - ^{11}C dihydrotetrabenazine isomer. 10

To date, so far as the applicants are aware, the dihydrotetrabenazine isomers derived from the unstable *RS* and *SR* isomers (hereinafter referred to individually or collectively as *cis*-tetrabenazine because the hydrogen atoms at the 3 and 11*b* positions have a *cis* relative orientation) of tetrabenazine have not previously been 15 isolated and characterised, and the biological activities of these compounds have not been published hitherto.

Summary of the Invention

It has now been found that dihydrotetrabenazine isomers derived from the unstable *RS* and *SR* isomers ("cis" isomers) of tetrabenazine are not only stable but have 20 unexpectedly good biological properties. In particular, certain of the isomers have receptor-activity profiles that are suggestive of a number of advantages over the *RR/SS* tetrabenazine currently in use. For example, several of the isomers, although having high affinity for VMAT2, show greatly reduced or negligible binding of dopamine receptors indicating that they are unlikely to give rise to the 25 dopaminergic side effects encountered with tetrabenazine. None of the isomers showed inhibition of the dopamine transporter (DAT). In addition, studies in rats on several of the isomers have shown that they lack the unwanted sedative side effects associated with tetrabenazine. The lack of sedative activity may be due to the very low affinities of some of the isomers for adrenergic receptors. 30 Furthermore, whereas one of the side effects of tetrabenazine is depression, several

of the dihydrotetrabenazine isomers show an affinity for the serotonin transporter (SERT) protein indicating that they may have antidepressant activity.

Accordingly, in a first aspect, the invention provides 3,11b-*cis*-dihydrotetrabenazine.

- 5 In another aspect, the invention provides a pharmaceutical composition comprising 3,11b-*cis*-dihydrotetrabenazine and a pharmaceutically acceptable carrier.

The invention also provides 3,11b-*cis*-dihydrotetrabenazine in substantially pure form, for example at an isomeric purity of greater than 90%, typically greater than 95% and more preferably greater than 98%.

- 10 The term "isomeric purity" in the present context refers to the amount of 3,11b-*cis*-dihydrotetrabenazine present relative to the total amount or concentration of dihydrotetrabenazine of all isomeric forms. For example, if 90% of the total dihydrotetrabenazine present in the composition is 3,11b-*cis*-dihydrotetrabenazine, then the isomeric purity is 90%.


- 15 The invention further provides a composition comprising 3,11b-*cis*-dihydrotetrabenazine substantially free of 3,11b-*trans*-dihydrotetrabenazine, preferably containing less than 5% of 3,11b-*trans*-dihydrotetrabenazine, more preferably less than 3% of 3,11b-*trans*-dihydrotetrabenazine, and most preferably less than 1% of 3,11b-*trans*-dihydrotetrabenazine.

- 20 In another aspect, the invention provides 3,11b-*cis*-dihydrotetrabenazine for use in medicine or therapy, for example in the treatment of hyperkinetic movement disorders such as Huntington's disease, hemiballismus, senile chorea, tic, tardive dyskinesia and Tourette's syndrome, or in the treatment of depression.

- In a further aspect, the invention provides the use of 3,11b-*cis*-dihydrotetrabenazine
25 for the manufacture of a medicament for the treatment of hyperkinetic movement disorders such as Huntington's disease, hemiballismus, senile chorea, tic, tardive dyskinesia and Tourette's syndrome, or the treatment of depression.


In a still further aspect, the invention provides a method for the prophylaxis or treatment of a hyperkinetic movement disorder such as Huntington's disease, hemiballismus, senile chorea, tic, tardive dyskinesia and Tourette's syndrome, or the treatment of depression in a patient in need of such prophylaxis or treatment, which method comprises the administration of an effective prophylactic or therapeutic amount of 3,11b-*cis*-dihydrotrabenazine.

The term "3,11b-*cis*-" as used herein means that the hydrogen atoms at the 3- and 11b-positions of the dihydrotrabenazine structure are in the *cis* relative orientation. The isomers of the invention are therefore compounds of the formula (I) and antipodes (mirror images) thereof.




There are four possible isomers of dihydrotrabenazine having the 3,11b-*cis* configuration and these are the 2*S*,3*S*,11b*R* isomer, the 2*R*,3*R*,11b*S* isomer, the 2*R*,3*S*,11b*R* isomer and the 2*S*,3*R*,11b*S* isomer. The four isomers have been isolated and characterised and, in another aspect, the invention provides individual isomers of 3,11b-*cis*-dihydrotrabenazine. In particular, the invention provides:


(a) the 2*S*,3*S*,11b*R* isomer of 3,11b-*cis*-dihydrotrabenazine having the formula (Ia):



(b) the 2*R*,3*R*,11b*S* isomer of 3,11b-*cis*-dihydrotrabenazine having the formula (Ib):




(c) the $2R,3S,11bR$ isomer of 3,11b-*cis*-dihydrotetraabenazine having the formula (Ic):



5 and

(d) the $2S,3R,11bS$ isomer of 3,11b-*cis*-dihydrotetraabenazine having the formula (Id):



The individual novel isomers of the invention can be characterised by their spectroscopic, optical and chromatographic properties.

Preferred isomers are the dextrorotatory (+) isomers.

Without implying any particular absolute configuration or stereochemistry, the four novel isomers may be characterised as follows:

Isomer A

15 Optical activity as measured by ORD (methanol, 21°C): laevorotatory (-)
 IR Spectrum (KBr solid), $^1\text{H-NMR}$ spectrum (CDCl_3) and $^{13}\text{C-NMR}$ spectrum (CDCl_3) substantially as described in Table 1.

Isomer B

Optical activity as measured by ORD (methanol, 21°C): dextrorotatory (+)
IR Spectrum (KBr solid), ¹H-NMR spectrum (CDCl₃) and ¹³C-NMR spectrum (CDCl₃) substantially as described in Table 1.

5 Isomer C

Optical activity as measured by ORD (methanol, 21°C): dextrorotatory (+)
IR Spectrum (KBr solid), ¹H-NMR spectrum (CDCl₃) and ¹³C-NMR spectrum (CDCl₃) substantially as described in Table 2.

Isomer D

10 Optical activity as measured by ORD (methanol, 21°C): laevorotatory (-)
IR Spectrum (KBr solid), ¹H-NMR spectrum (CDCl₃) and ¹³C-NMR spectrum (CDCl₃) substantially as described in Table 2.

ORD values for each isomer are given in the examples below but it is noted that such values are given by way of example and may vary according to the degree of
15 purity of the isomer and the influence of other variables such as temperature fluctuations and the effects of residual solvent molecules.

The enantiomers A, B, C and D may each be presented in a substantially enantiomerically pure form or as mixtures with other enantiomers of the invention.

The terms “enantiomeric purity” and “enantiomerically pure” in the present context
20 refer to the amount of a given enantiomer of 3,11b-*cis*-dihydrotetabenazine present relative to the total amount or concentration of dihydrotetabenazine of all enantiomeric and isomeric forms. For example, if 90% of the total dihydrotetabenazine present in the composition is in the form of a single enantiomer, then the enantiomeric purity is 90%.

25 By way of example, in each aspect and embodiment of the invention, each individual enantiomer selected from Isomers A, B, C and D may be present in an enantiomeric purity of at least 55% (e.g. at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, 99.5% or 100%).

The isomers of the invention may also be presented in the form of mixtures of one or more of Isomers A, B, C and D. Such mixtures may be racemic mixtures or non-racemic mixtures. Examples of racemic mixtures include the racemic mixture of Isomer A and Isomer B and the racemic mixture of Isomer C and Isomer D.

5 **Pharmaceutically Acceptable Salts**

Unless the context requires otherwise, a reference in this application to dihydrotetrabenazine and its isomers, includes within its scope not only the free base of the dihydrotetrabenazine but also its salts, and in particular acid addition salts.

- 10 Particular acids from which the acid addition salts are formed include acids having a pKa value of less than 3.5 and more usually less than 3. For example, the acid addition salts can be formed from an acid having a pKa in the range from +3.5 to -3.5.

- 15 Preferred acid addition salts include those formed with sulphonic acids such as methanesulphonic acid, ethanesulphonic acid, benzene sulphonic acid, toluene sulphonic acid, camphor sulphonic acid and naphthalene sulphonic acid.

One particular acid from which acid addition salts may be formed is methanesulphonic acid.


- 20 Acid addition salts can be prepared by the methods described herein or conventional chemical methods such as the methods described in *Pharmaceutical Salts: Properties, Selection, and Use*, P. Heinrich Stahl (Editor), Camille G. Wermuth (Editor), ISBN: 3-90639-026-8, Hardcover, 388 pages, August 2002. Generally, such salts can be prepared by reacting the free base form of the compound with the appropriate base or acid in water or in an organic solvent, or in
25 a mixture of the two; generally, nonaqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are used.

The salts are typically pharmaceutically acceptable salts. However, salts that are not pharmaceutically acceptable may also be prepared as intermediate forms which

may then be converted into pharmaceutically acceptable salts. Such non-pharmaceutically acceptable salt forms also form part of the invention.

Methods for the Preparation of Dihydratetabenazine Isomers

In a further aspect, there is provided a process (Process A) for preparing a dihydratetabenazine of the invention, which process comprises the reaction of a compound of the formula (II):



with a reagent or reagents suitable for hydrating the 2,3-double bond in the compound of formula (II) and thereafter where required separating and isolating a desired dihydratetabenazine isomer form.

The hydration of the 2,3-double bond can be carried out by hydroboration using a borane reagent such as diborane or a borane-ether (e.g. borane-tetrahydrofuran (THF)) to give an intermediate alkyl borane adduct followed by oxidation of the alkyl borane adduct and hydrolysis in the presence of a base. The hydroboration is typically carried out in a dry polar non-protic solvent such as an ether (e.g. THF), usually at a non-elevated temperature, for example room temperature. The borane-alkene adduct is typically oxidised with an oxidising agent such as hydrogen peroxide in the presence of a base providing a source of hydroxide ions, such as ammonium hydroxide or an alkali metal hydroxide, e.g. potassium hydroxide or sodium hydroxide. The hydroboration-oxidation-hydrolysis sequence of reactions of Process A typically provides dihydratetabenazine isomers in which the hydrogen atoms at the 2- and 3-positions have a *trans* relative orientation.

Compounds of the formula (II) can be prepared by reduction of tetabenazine to give a dihydratetabenazine followed by dehydration of the dihydratetabenazine. Reduction of the tetabenazine can be accomplished using an aluminium hydride reagent such as lithium aluminium hydride, or a borohydride reagent such as sodium borohydride, potassium borohydride or a borohydride derivative, for

example an alkyl borohydride such as lithium tri-*sec*-butyl borohydride.


Alternatively, the reduction step can be effected using catalytic hydrogenation, for example over a Raney nickel or platinum oxide catalyst. Suitable conditions for performing the reduction step are described in more detail below or can be found in
5 US 2,843,591 (Hoffmann- La Roche) and Brossi *et al.*, *Helv. Chim. Acta.*, vol. XLI, No. 193, pp1793-1806 (1958).

Because the tetrabenazine used as the starting material for the reduction reaction is typically a mixture of the *RR* and *SS* isomers (i.e. *trans*-tetrabenazine), the dihydrotetrabenazine formed by the reduction step will have the same *trans*
10 configuration about the 3- and 11b positions and will take the form of one or more of the known dihydrotetrabenazine isomers shown in Figure 3 above. Thus Process A may involve taking the known isomers of dihydrotetrabenazine, dehydrating them to form the alkene (II) and then "rehydrating" the alkene (II) using conditions that give the required novel *cis* dihydrotetrabenazine isomers of the invention.

15 Dehydration of the dihydrotetrabenazine to the alkene (II) can be carried out using a variety of standard conditions for dehydrating alcohols to form alkenes, see for example J. March (*idem*) pages 389-390 and references therein. Examples of such conditions include the use of phosphorus-based dehydrating agents such as phosphorus halides or phosphorus oxyhalides, e.g. POCl₃ and PCl₅. As an
20 alternative to direct dehydration, the hydroxyl group of the dihydrotetrabenazine can be converted to a leaving group L such as halogen (e.g. chlorine or bromine) and then subjected to conditions (e.g. the presence of a base) for eliminating H-L. Conversion of the hydroxyl group to a halide can be achieved using methods well known to the skilled chemist, for example by reaction with carbon tetrachloride or
25 carbon tetrabromide in the presence of a trialkyl or triaryl phosphine such as triphenyl phosphine or tributyl phosphine.

The tetrabenazine used as the starting material for the reduction to give the dihydrotetrabenazine can be obtained commercially or can be synthesised by the method described in US 2,830,993 (Hoffmann-La Roche).

The invention also provides a process (Process B) for preparing a dihydrotetrabenazine of the invention, which process comprises subjecting a compound of the formula (III):



5 to conditions for ring-opening the 2,3-epoxide group in the compound of the formula (III), and thereafter where required separating and isolating a desired dihydrotetrabenazine isomer form.

The ring-opening can be effected in accordance with known methods for epoxide ring openings. However, a currently preferred method of ring-opening the epoxide
 10 is reductive ring opening which can be achieved using a reducing agent such as borane-THF. Reaction with borane-THF can be carried out in a polar non-protic solvent such as an ether (e.g. tetrahydrofuran) usually at ambient temperature, the borane complex thus formed being subsequently hydrolysed by heating in the presence of water and a base at the reflux temperature of the solvent. Process B
 15 typically gives rise to dihydrotetrabenazine isomers in which the hydrogen atoms at the 2- and 3-positions have a *cis* relative orientation.


The epoxide compounds of the formula (III) can be prepared by epoxidation of an alkene of the formula (II) above. The epoxidation reaction can be carried out using conditions and reagents well known to the skilled chemist, see for example J.
 20 March (*idem*), pages 826-829 and references therein. Typically, a per-acid such as *meta*-chloroperbenzoic acid (MCPBA), or a mixture of a per-acid and a further oxidising agent such as perchloric acid, may be used to bring about epoxidation.

When the starting materials for processes A and B above are mixtures of enantiomers, then the products of the processes will typically be pairs of
 25 enantiomers, for example racemic mixtures, possibly together with diastereoisomeric impurities. Unwanted diastereoisomers can be removed by techniques such as chromatography (e.g. HPLC) and the individual enantiomers can

be separated by a variety of methods known to the skilled chemist. For example, they can be separated by means of:

- (i) chiral chromatography (chromatography on a chiral support); or
- (ii) forming a salt with an optically pure chiral acid, separating the salts of the two diastereoisomers by fractional crystallisation and then releasing the dihydrotetrabenazine from the salt; or
- (iii) forming a derivative (such as an ester) with an optically pure chiral derivatising agent (e.g. esterifying agent), separating the resulting epimers (e.g. by chromatography) and then converting the derivative to the dihydrotetrabenazine.

- 10 One method of separating pairs of enantiomers obtained from each of Processes A and B, and which has been found to be particularly effective, is to esterify the hydroxyl group of the dihydrotetrabenazine with an optically active form of Mosher's acid, such as the *R* (+) isomer shown below, or an active form thereof:




- 15 The resulting esters of the two enantiomers of the dihydrobenazine can then be separated by chromatography (e.g. HPLC) and the separated esters hydrolysed to give the individual dihydrobenazine isomers using a base such as an alkali metal hydroxide (e.g. NaOH) in a polar solvent such as methanol.

- As an alternative to using mixtures of enantiomers as the starting materials in processes A and B and then carrying out separation of enantiomers subsequently, processes A and B can each be carried out on single enantiomer starting materials leading to products in which a single enantiomer predominates. Single enantiomers of the alkene (II) can be prepared by subjecting RR/SS tetrabenazine to a stereoselective reduction using lithium tri-*sec*-butyl borohydride to give a mixture of SRR and RSS enantiomers of dihydrotetrabenazine, separating the enantiomers (e.g. by fractional crystallisation) and then dehydrating a separated single enantiomer of dihydrotetrabenazine to give predominantly or exclusively a single enantiomer of the compound of formula (II).

Processes A and B are illustrated in more detail below in Schemes 1 and 2 respectively.

Scheme 1



Scheme 1 illustrates the preparation of individual dihydrotetrabenazine isomers
 5 having the $2S,3S,11bR$ and $2R,3R,11bS$ configurations in which the hydrogen atoms
 attached to the 2- and 3-positions are arranged in a *trans* relative orientation. This
 reaction scheme includes Process A defined above.

The starting point for the sequence of reactions in Scheme 1 is commercially
 available tetrabenazine (IV) which is a racemic mixture of the *RR* and *SS* optical
 10 isomers of tetrabenazine. In each of the *RR* and *SS* isomers, the hydrogen atoms at
 the 3- and 11b-positions are arranged in a *trans* relative orientation. As an

alternative to using the commercially available compound, tetrabenazine can be synthesised according to the procedure described in US patent number 2,830,993 (see in particular example 11).

The racemic mixture of RR and SS tetrabenazine is reduced using the borohydride reducing agent lithium tri-*sec*-butyl borohydride ("L-Selectride") to give a mixture of the known 2*S*,3*R*,11*bR* and 2*R*,3*S*,11*bS* isomers (V) of dihydrotetrabenazine, of which only the 2*S*,3*R*,11*bR* isomer is shown for simplicity. By using the more sterically demanding L-Selectride as the borohydride reducing agent rather than sodium borohydride, formation of the RRR and SSS isomers of dihydro-
10 tetrabenazine is minimised or suppressed.

The dihydrotetrabenazine isomers (V) are reacted with a dehydrating agent such as phosphorus pentachloride in a non-protic solvent such as a chlorinated hydrocarbon (for example chloroform or dichloromethane, preferably dichloromethane) to form the unsaturated compound (II) as a pair of enantiomers, only the *R*-enantiomer of
15 which is shown in the Scheme. The dehydration reaction is typically carried out at a temperature lower than room temperature, for example at around 0-5°C.

The unsaturated compound (II) is then subjected to a stereoselective re-hydration to generate the dihydrotetrabenazine (VI) and its mirror image or antipode (not shown) in which the hydrogen atoms at the 3- and 11*b*-positions are arranged in a
20 *cis* relative orientation and the hydrogen atoms at the 2- and 3-positions are arranged in a *trans* relative orientation. The stereoselective rehydration is accomplished by a hydroboration procedure using borane-THF in tetrahydrofuran (THF) to form an intermediate borane complex (not shown) which is then oxidised with hydrogen peroxide in the presence of a base such as sodium hydroxide.

25 An initial purification step may then be carried out (e.g. by HPLC) to give the product (V) of the rehydration reaction sequence as a mixture of the 2*S*,3*S*,11*bR* and 2*R*,3*R*,11*bS* isomers of which only the 2*S*,3*S*,11*bR* isomer is shown in the Scheme. In order to separate the isomers, the mixture is treated with *R* (+) Mosher's acid, in the presence of oxalyl chloride and dimethylaminopyridine
30 (DMAP) in dichloromethane to give a pair of diastereoisomeric esters (VII) (of


which only one diastereoisomer is shown) which can then be separated using HPLC. The individual esters can then be hydrolysed using an alkali metal hydroxide such as sodium hydroxide to give a single isomer (VI).

In a variation of the sequence of steps shown in Scheme 1, following the reduction of RR/SS tetrabenazine, the resulting mixture of enantiomers of the dihydrotetrabenazine (V) can be separated to give the individual enantiomers. Separation can be carried out by forming a salt with a chiral acid such as (+) or (-) camphorsulphonic acid, separating the resulting diastereoisomers by fractional crystallisation to give a salt of a single enantiomer and then releasing the free base from the salt.

The separated dihydrotetrabenazine enantiomer can be dehydrated to give a single enantiomer of the alkene (II). Subsequent rehydration of the alkene (II) will then give predominantly or exclusively a single enantiomer of the cis-dihydrotetrabenazine (VI). An advantage of this variation is that it does not involve the formation of Mosher's acid esters and therefore avoids the chromatographic separation typically used to separate Mosher's acid esters.

Scheme 2 illustrates the preparation of individual dihydrotetrabenazine isomers having the $2R,3S,11bR$ and $2S,3R,11bS$ configurations in which the hydrogen atoms attached to the 2- and 3-positions are arranged in a *cis* relative orientation. This reaction scheme includes Process B defined above.

Scheme 2



In Scheme 2, the unsaturated compound (II) is produced by reducing tetrabenazine to give the 2S,3R,11bR and 2R,3S,11bS isomers (V) of dihydrotetrabenazine and dehydrating with PCl_5 in the manner described above in Scheme 1. However, instead of subjecting the compound (II) to hydroboration, the 2,3-double bond is converted to an epoxide by reaction with *meta*-chloroperbenzoic acid (MCPBA) and perchloric acid. The epoxidation reaction is conveniently carried out in an alcohol solvent such as methanol, typically at around room temperature.

The epoxide (VII) is then subjected to a reductive ring opening using borane-THF as an electrophilic reducing agent to give an intermediate borane complex (not shown) which is then oxidised and cleaved with hydrogen peroxide in the presence

of an alkali such as sodium hydroxide to give a dihydrotetrabenazine (VIII) as a mixture of the *2R,3S,11bR* and *2S,3R,11bS* isomers, of which only the *2R,3S,11bR* is shown for simplicity. Treatment of the mixture of isomers (VIII) with *R* (+) Mosher's acid in the presence of oxalyl chloride and dimethylaminopyridine (DMAP) in dichloromethane gives a pair of epimeric esters (IX) (of which only one epimer is shown) which can then be separated by chromatography and hydrolysed with sodium hydroxide in methanol in the manner described above in relation to Scheme 1.

The chemical intermediates (II) and (III) are believed to be new and represent a further aspect of the invention.

Biological Properties and Therapeutic Uses

Tetrabenazine exerts its therapeutic effects by inhibiting the vesicular monoamine transporter VMAT2 in the brain and by inhibiting both pre-synaptic and post-synaptic dopamine receptors.

The novel dihydrotetrabenazine isomers of the invention are also inhibitors of VMAT2, with Isomers C and B producing the greatest degree of inhibition. Like tetrabenazine, the compounds of the invention have only a low affinity for VMAT1, the VMAT isoform found in peripheral tissues and some endocrine cells, thereby indicating that they should not produce the side effects associated with reserpine. Compounds C and B also exhibit no inhibitory activity against catechol O-methyl transferase (COMT), monoamine oxidase isoforms A and B, and 5-hydroxytryptamine isoforms 1d and 1b.

Surprisingly, isomers C and B also show a remarkable separation of VMAT2 and dopamine receptor activity in that although they are highly active in binding VMAT2, both compounds exhibit only weak or non-existent dopamine receptor binding activity and lack Dopamine Transporter (DAT) binding activity. In fact, none of the isomers exhibit significant DAT binding activity. This suggests that the compounds may lack the dopaminergic side effects produced by tetrabenazine. Isomers C and B are also either weakly active or inactive as inhibitors of the adrenergic receptors and this suggests that the compounds may lack the adrenergic

side effects often encountered with tetrabenazine. In fact, in locomotor studies carried out on rats, tetrabenazine exhibited a dose related sedative effect, whereas no sedative effects were observed following administration of the dihydrotetrabenazine isomers B and C of the invention.

- 5 Furthermore, both Isomer C and Isomer B are potent inhibitors of the serotonin transporter protein SERT. Inhibition of SERT is one mechanism by which antidepressants such as fluoxetine (Prozac®) exert their therapeutic effects. Therefore, the ability of Isomers C and B to inhibit SERT indicates that these isomers may act as antidepressants, in marked contrast to tetrabenazine for which
10 depression is a well recognised side effect.

On the basis of the studies carried out to date, it is envisaged that the dihydrotetrabenazine compounds of the invention will be useful in the prophylaxis or treatment of the disease states and conditions for which tetrabenazine is currently used or proposed. Thus, by way of example, and without limitation, the
15 dihydrotetrabenazine compounds of the invention may be used for the treatment of hyperkinetic movement disorders such as Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, dystonia and Tourette's syndrome.

It is also envisaged that the dihydrotetrabenazine compounds of the invention may be useful in the treatment of depression.

- 20 The compounds will generally be administered to a subject in need of such administration, for example a human or animal patient, preferably a human.

The compounds will typically be administered in amounts that are therapeutically or prophylactically useful and which generally are non-toxic. However, in certain situations, the benefits of administering a dihydrotetrabenazine compound of the
25 invention may outweigh the disadvantages of any toxic effects or side effects, in which case it may be considered desirable to administer compounds in amounts that are associated with a degree of toxicity.

A typical daily dose of the compound can be in the range from 0.025 milligrams to 5 milligrams per kilogram of body weight, for example up to 3 milligrams per

kilogram of bodyweight, and more typically 0.15 milligrams to 5 milligrams per kilogram of bodyweight although higher or lower doses may be administered where required.

By way of example, an initial starting dose of 12.5 mg may be administered 2 to 3 times a day. The dosage can be increased by 12.5 mg a day every 3 to 5 days until the maximal tolerated and effective dose is reached for the individual as determined by the physician. Ultimately, the quantity of compound administered will be commensurate with the nature of the disease or physiological condition being treated and the therapeutic benefits and the presence or absence of side effects produced by a given dosage regimen, and will be at the discretion of the physician.

Pharmaceutical Formulations

The invention also provides dihydrotetrabenazine compounds as hereinbefore defined in the form of pharmaceutical compositions.

The pharmaceutical compositions can be in any form suitable for oral, parenteral, topical, intranasal, intrabronchial, ophthalmic, otic, rectal, intra-vaginal, or transdermal administration. Where the compositions are intended for parenteral administration, they can be formulated for intravenous, intramuscular, intraperitoneal, subcutaneous administration or for direct delivery into a target organ or tissue by injection, infusion or other means of delivery.

Pharmaceutical dosage forms suitable for oral administration include tablets, capsules, caplets, pills, lozenges, syrups, solutions, sprays, powders, granules, elixirs and suspensions, sublingual tablets, sprays, wafers or patches and buccal patches.

Pharmaceutical compositions containing the dihydrotetrabenazine compounds of the invention can be formulated in accordance with known techniques, see for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, USA.

Thus, tablet compositions can contain a unit dosage of active compound together with an inert diluent or carrier such as a sugar or sugar alcohol, e.g.; lactose,

sucrose, sorbitol or mannitol; and/or a non-sugar derived diluent such as sodium carbonate, calcium phosphate, talc, calcium carbonate, or a cellulose or derivative thereof such as methyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose, and starches such as corn starch. Tablets may also contain such standard
5 ingredients as binding and granulating agents such as polyvinylpyrrolidone, disintegrants (e.g. swellable crosslinked polymers such as crosslinked carboxymethylcellulose), lubricating agents (e.g. stearates), preservatives (e.g. parabens), antioxidants (e.g. BHT), buffering agents (for example phosphate or citrate buffers), and effervescent agents such as citrate/bicarbonate mixtures. Such
10 excipients are well known and do not need to be discussed in detail here.

Capsule formulations may be of the hard gelatin or soft gelatin variety and can contain the active component in solid, semi-solid, or liquid form. Gelatin capsules can be formed from animal gelatin or synthetic or plant derived equivalents thereof.

The solid dosage forms (e.g.; tablets, capsules etc.) can be coated or un-coated, but
15 typically have a coating, for example a protective film coating (e.g. a wax or varnish) or a release controlling coating. The coating (e.g. a Eudragit™ type polymer) can be designed to release the active component at a desired location within the gastro-intestinal tract. Thus, the coating can be selected so as to degrade under certain pH conditions within the gastrointestinal tract, thereby selectively
20 release the compound in the stomach or in the ileum or duodenum.

Instead of, or in addition to, a coating, the drug can be presented in a solid matrix comprising a release controlling agent, for example a release delaying agent which may be adapted to selectively release the compound under conditions of varying acidity or alkalinity in the gastrointestinal tract. Alternatively, the matrix material
25 or release retarding coating can take the form of an erodible polymer (e.g. a maleic anhydride polymer) which is substantially continuously eroded as the dosage form passes through the gastrointestinal tract.

Compositions for topical use include ointments, creams, sprays, patches, gels, liquid drops and inserts (for example intraocular inserts). Such compositions can be
30 formulated in accordance with known methods.

Compositions for parenteral administration are typically presented as sterile aqueous or oily solutions or fine suspensions, or may be provided in finely divided sterile powder form for making up extemporaneously with sterile water for injection.

- 5 Examples of formulations for rectal or intra-vaginal administration include pessaries and suppositories which may be, for example, formed from a shaped mouldable or waxy material containing the active compound.

Compositions for administration by inhalation may take the form of inhalable powder compositions or liquid or powder sprays, and can be administered in
10 standard form using powder inhaler devices or aerosol dispensing devices. Such devices are well known. For administration by inhalation, the powdered formulations typically comprise the active compound together with an inert solid powdered diluent such as lactose.

The compounds of the inventions will generally be presented in unit dosage form
15 and, as such, will typically contain sufficient compound to provide a desired level of biological activity. For example, a formulation intended for oral administration may contain from 2 milligrams to 200 milligrams of active ingredient, more usually from 10 milligrams to 100 milligrams, for example, 12.5 milligrams, 25 milligrams and 50 milligrams.

- 20 The active compound will be administered to a patient in need thereof (for example a human or animal patient) in an amount sufficient to achieve the desired therapeutic effect.


EXAMPLES

The following non-limiting examples illustrate the synthesis and properties of the
25 dihydrotetrabenazine compounds of the invention.

EXAMPLE 1

Preparation of 2*S*,3*S*,11*bR* and 2*R*,3*R*,11*bS* Isomers of Dihydrotetrabenazine

1A. Reduction of *RR/SS* Tetrabenazine




1M L-Selectride[®] in tetrahydrofuran (135 ml, 135 mmol, 2.87 eq.) was added slowly over 30 minutes to a stirred solution of tetrabenazine *RR/SS* racemate (15 g, 47 mmol) in ethanol (75 ml) and tetrahydrofuran (75 ml) at 0 °C. After addition
 5 was complete the mixture was stirred at 0 °C for 30 minutes and then allowed to warm to room temperature.

The mixture was poured onto crushed ice (300 g) and water (100 ml) added. The solution was extracted with diethyl ether (2 x 200 ml) and the combined ethereal extracts washed with water (100 ml) and partly dried over anhydrous potassium
 10 carbonate. Drying was completed using anhydrous magnesium sulphate and, after filtration, the solvent was removed at reduced pressure (shielded from the light, bath temperature <20 °C) to afford a pale yellow solid.

The solid was slurried with petroleum ether (30-40 °C) and filtered to afford a white powdery solid (12 g, 80%).


15 1B. Dehydration of reduced Tetrabenazine



Phosphorous pentachloride (32.8 g, 157.5 mmol, 2.5 eq) was added in portions over 30 minutes to a stirred solution of the reduced tetrabenazine product from Example 1A (20 g, 62.7 mmol) in dichloromethane (200 ml) at 0 °C. After the addition was complete, the reaction mixture was stirred at 0 °C for a further 30 minutes and the solution poured slowly into 2M aqueous sodium carbonate solution containing crushed ice (0 °C). Once the initial acid gas evolution had ceased the mixture was basified (ca. pH 12) using solid sodium carbonate.

The alkaline solution was extracted using ethyl acetate (800 ml) and the combined organic extracts dried over anhydrous magnesium sulphate. After filtration the solvent was removed at reduced pressure to afford a brown oil, which was purified by column chromatography (silica, ethyl acetate) to afford the semi-pure alkene as a yellow solid (10.87 g, 58%).

1C. Hydration of the Crude Alkene from Example 1B




A solution of the crude alkene (10.87 g, 36.11 mmol) from Example 1B in dry THF (52 ml) at room temperature was treated with 1M borane-THF (155.6 ml, 155.6 mmol, 4.30 eq) added in a dropwise manner. The reaction was stirred for 2 hours, water (20 ml) was added and the solution basified to pH 12 with 30% aqueous sodium hydroxide solution.

Aqueous 30% hydrogen peroxide solution (30 ml) was added to the stirred alkaline reaction mixture and the solution was heated to reflux for 1 hour before being allowed to cool. Water (100 ml) was added and the mixture extracted with ethyl acetate (3 x 250 ml). The organic extracts were combined and dried over

anhydrous magnesium sulphate and after filtration the solvent was removed at reduced pressure to afford a yellow oil (9 g).

The oil was purified using preparative HPLC (Column: Lichrospher Si60, 5 μm , 250 x 21.20 mm, mobile phase: hexane : ethanol : dichloromethane (85:15:5); UV 254 nm, flow: 10 ml min⁻¹) at 350 mg per injection followed by concentration of the fractions of interest under vacuum. The product oil was then dissolved in ether and concentrated once more under vacuum to give the dihydrotetrabenazine racemate shown above as a yellow foam (5.76 g, 50%).

1D. Preparation of Mosher's ester derivatives



R-(+)- α -methoxy- α -trifluoromethylphenyl acetic acid (5 g, 21.35 mmol), oxalyl chloride (2.02 ml) and DMF (0.16 ml) were added to anhydrous dichloromethane (50 ml) and the solution was stirred at room temperature for 45 minutes. The solution was concentrated under reduced pressure and the residue was taken up in anhydrous dichloromethane (50 ml) once more. The resulting solution was cooled using an ice-water bath and dimethylaminopyridine (3.83 g, 31.34 mmol) was added followed by a pre-dried solution (over 4 \AA sieves) in anhydrous dichloromethane of the solid product of Example 1C (5 g, 15.6 mmol). After stirring at room temperature for 45 minutes, water (234 ml) was added and the mixture extracted with ether (2 x 200 ml). The ether extract was dried over anhydrous magnesium sulphate, passed through a pad of silica and the product eluted using ether.

15

20

The collected ether eluate was concentrated under reduced pressure to afford an oil which was purified using column chromatography (silica, hexane : ether (10:1)). Evaporation of the collected column fractions of interest and removal of the solvent

25


at reduced pressure gave a solid which was further purified using column chromatography (silica, hexane : ethyl acetate (1:1)) to give three main components which were partially resolved into Mosher's ester peaks 1 and 2.

Preparative HPLC of the three components (Column: 2 x Lichrospher Si60, 5 μm , 250 x 21.20 mm, mobile phase: hexane : isopropanol (97:3), UV 254 nm; flow: 10 ml min⁻¹) at 300 mg loading followed by concentration of the fractions of interest under vacuum gave the pure Mosher's ester derivatives

Peak 1 (3.89 g, 46.5%)

Peak 2 (2.78 g, 33%)

10 The fractions corresponding to the two peaks were subjected to hydrolysis to liberate the individual dihydrotetrabenazine isomers identified and characterised as Isomers A and B. Isomers A and B are each believed to have one of the following structures



15 1E. Hydrolysis of Peak 1 to give Isomer A

Aqueous 20% sodium hydroxide solution (87.5 ml) was added to a solution of Mosher's ester peak 1 (3.89 g, 7.27 mmol) in methanol (260 ml) and the mixture stirred and heated to reflux for 150 minutes. After cooling to room temperature water (200 ml) was added and the solution extracted with ether (600 ml), dried over anhydrous magnesium sulphate and after filtration, concentrated under reduced pressure.

The residue was dissolved using ethyl acetate (200 ml), the solution washed with water (2 x 50 ml), the organic phase dried over anhydrous magnesium sulphate and after filtration, concentrated under reduced pressure to give a yellow foam. This material was purified by column chromatography (silica, gradient elution of ethyl

acetate : hexane (1:1) to ethyl acetate). The fractions of interest were combined and the solvent removed at reduced pressure. The residue was taken up in ether and the solvent removed at reduced pressure once more to give Isomer A as an off-white foam (1.1 g, 47%).

- 5 Isomer A, which is believed to have either the *2S,3S,11bR* or *2R,3R,11bS* configuration (the absolute stereochemistry was not determined), was characterized by ¹H-NMR, ¹³C-NMR, IR, mass spectrometry, chiral HPLC and ORD. The IR, NMR and MS data for isomer A are set out in Table 1 and the Chiral HPLC and ORD data are set out in Table 3.

10 1F. Hydrolysis of Peak 2 to give Isomer B

Aqueous 20% sodium hydroxide solution (62.5 ml) was added to a solution of Mosher's ester peak 2 (2.78 g, 5.19 mmol) in methanol (185 ml) and the mixture stirred and heated to reflux for 150 minutes. After cooling to room temperature water (142 ml) was added and the solution extracted with ether (440 ml), dried over
15 anhydrous magnesium sulphate and after filtration, concentrated under reduced pressure.

The residue was dissolved using ethyl acetate (200 ml), the solution washed with water (2 x 50 ml), the organic phase dried over anhydrous magnesium sulphate and after filtration, concentrated under reduced pressure. Petroleum ether (30-40 °C)
20 was added to the residue and the solution concentrated under vacuum once more to give Isomer B as a white foam (1.34 g, 81%).

Isomer B, which is believed to have either the *2S,3S,11bR* or *2R,3R,11bS* configuration (the absolute stereochemistry was not determined), was characterized by ¹H-NMR, ¹³C-NMR, IR, mass spectrometry, chiral HPLC and ORD. The IR,
25 NMR and MS data for Isomer B are set out in Table 1 and the Chiral HPLC and ORD data are set out in Table 3.


EXAMPLE 2

Preparation of *2R,3S,11bR* and *2S,3R,11bS* Isomers of Dihydratetabenazine


2A. Preparation of 2,3-Dehydrotetrabenazine

A solution containing a racemic mixture (15 g, 47 mmol) of *RR* and *SS* tetrabenazine enantiomers in tetrahydrofuran was subjected to reduction with L-Selectride[®] by the method of Example 1A to give a mixture of the *2S,3R,11bR* and *2R,3S,11bS* enantiomers of dihydrotetrabenazine as a white powdery solid (12 g, 80%). The partially purified dihydrotetrabenazine was then dehydrated using PCl_5 according to the method of Example 1B to give a semi-pure mixture of *11bR* and *11bS* isomers of 2,3-dehydrotetrabenazine (the *11bR* enantiomer of which is shown below) as a yellow solid (12.92 g, 68%).

10



2B. Epoxidation of the Crude Alkene from Example 2A




To a stirred solution of the crude alkene from Example 2A (12.92 g, 42.9 mmol) in methanol (215 ml) was added a solution of 70% perchloric acid (3.70 ml, 43 mmol) in methanol (215 ml). 77% 3-Chloroperoxybenzoic acid (15.50 g, 65 mmol) was added to the reaction and the resulting mixture was stirred for 18 hours at room temperature protected from light.

The reaction mixture was poured into saturated aqueous sodium sulphite solution (200 ml) and water (200 ml) added. Chloroform (300 ml) was added to the resulting emulsion and the mixture basified with saturated aqueous sodium bicarbonate (400 ml).

20

The organic layer was collected and the aqueous phase washed with additional chloroform (2 x 150 ml). The combined chloroform layers were dried over anhydrous magnesium sulphate and after filtration the solvent was removed at reduced pressure to give a brown oil (14.35 g, yield > 100% - probable solvent remains in product). This material was used without further purification.

2C. Reductive Ring Opening of the Epoxide from 2B




A stirred solution of the crude epoxide from Example 2B (14.35 g, 42.9 mmol, assuming 100% yield) in dry THF (80 ml) was treated slowly with 1M borane/THF (184.6 ml, 184.6 mmol) over 15 minutes. The reaction was stirred for two hours, water (65 ml) was added and the solution heated with stirring to reflux for 30 minutes.

After cooling, 30% sodium hydroxide solution (97 ml) was added to the reaction mixture followed by 30% hydrogen peroxide solution (48.6 ml) and the reaction was stirred and heated to reflux for an additional 1 hour.

The cooled reaction mixture was extracted with ethyl acetate (500 ml) dried over anhydrous magnesium sulphate and after filtration the solvent was removed at reduced pressure to give an oil. Hexane (230 ml) was added to the oil and the solution re-concentrated under reduced pressure.

The oily residue was purified by column chromatography (silica, ethyl acetate). The fractions of interest were combined and the solvent removed under reduced pressure. The residue was purified once more using column chromatography (silica, gradient, hexane to ether). The fractions of interest were combined and the solvents evaporated at reduced pressure to give a pale yellow solid (5.18 g, 38%).

2D. Preparation of Mosher's ester derivatives of the 2*R*,3*S*,11*bR* and 2*S*,3*R*,11*bS* Isomers of Dihydratotetabenazine



R-(+)- α -methoxy- α -trifluoromethylphenyl acetic acid (4.68 g, 19.98 mmol), oxalyl chloride (1.90 ml) and DMF (0.13 ml) were added to anhydrous dichloromethane (46 ml) and the solution stirred at room temperature for 45 minutes. The solution was concentrated under reduced pressure and the residue was taken up in anhydrous dichloromethane (40 ml) once more. The resulting solution was cooled using an ice-water bath and dimethylaminopyridine (3.65 g, 29.87 mmol) was added followed by a pre-dried solution (over 4Å sieves) in anhydrous dichloromethane (20 ml) of the solid product of Example 2C (4.68 g, 14.6 mmol). After stirring at room temperature for 45 minutes, water (234 ml) was added and the mixture extracted with ether (2 x 200 ml). The ether extract was dried over anhydrous magnesium sulphate, passed through a pad of silica and the product eluted using ether.


The collected ether eluate was concentrated under reduced pressure to afford an oil which was purified using column chromatography (silica, hexane : ether (1:1)). Evaporation of the collected column fractions of interest and removal of the solvent at reduced pressure gave a pink solid (6.53 g)

Preparative HPLC of the solid (Column: 2 x Lichrospher Si60, 5 μm , 250 x 21.20 mm; mobile phase hexane : isopropanol (97:3); UV 254 nm; flow: 10 ml min⁻¹) at 100 mg loading followed by concentration of the fractions of interest under vacuum gave a solid which was slurried with petroleum ether (30-40 °C) and collected by
5 filtration to give the pure Mosher's ester derivatives

Peak 1 (2.37 g, 30%)

Peak 2 (2.42 g, 30%)

The fractions corresponding to the two peaks were subjected to hydrolysis to liberate the individual dihydrotetrabenazine isomers identified and characterised as
10 Isomers C and D. Isomers C and D are each believed to have one of the following structures



2F. Hydrolysis of Peak 1 to give Isomer C

20% aqueous sodium hydroxide solution (53 ml) was added to a stirred solution of
15 Mosher's ester peak 1 (2.37 g, 4.43 mmol) in methanol (158 ml) and the mixture stirred at reflux for 150 minutes. After cooling water (88 ml) was added to the reaction mixture and the resulting solution extracted with ether (576 ml). The organic extract was dried over anhydrous magnesium sulphate and after filtration the solvent removed at reduced pressure. Ethyl acetate (200 ml) was added to the
20 residue and the solution washed with water (2 x 50 ml). The organic solution was dried over anhydrous magnesium sulphate and after filtration the solvent removed at reduced pressure.

This residue was treated with petroleum ether (30-40 °C) and the resulting suspended solid collected by filtration. The filtrate was concentrated at reduced
25 pressure and the second batch of suspended solid was collected by filtration. Both

collected solids were combined and dried under reduced pressure to give Isomer C (1.0 g, 70%).

Isomer C, which is believed to have either the *2R,3S,11bR* or *2S,3R,11bS* configuration (the absolute stereochemistry was not determined), was characterized
5 by ¹H-NMR, ¹³C-NMR, IR, mass spectrometry, chiral HPLC and ORD. The IR, NMR and MS data for Isomer C are set out in Table 2 and the Chiral HPLC and ORD data are set out in Table 4.

2G. Hydrolysis of Peak 2 to give Isomer D

20% aqueous sodium hydroxide solution (53 ml) was added to a stirred solution of
10 Mosher's ester peak 2 (2.42 g, 4.52 mmol) in methanol (158 ml) and the mixture stirred at reflux for 150 minutes. After cooling water (88 ml) was added to the reaction mixture and the resulting solution extracted with ether (576 ml). The organic extract was dried over anhydrous magnesium sulphate and after filtration the solvent removed at reduced pressure. Ethyl acetate (200 ml) was added to the
15 residue and the solution washed with water (2 x 50 ml). The organic solution was dried over anhydrous magnesium sulphate and after filtration the solvent removed at reduced pressure.

This residue was treated with petroleum ether (30-40 °C) and the resulting suspended orange solid collected by filtration. The solid was dissolved in ethyl
20 acetate : hexane (15:85) and purified by column chromatography (silica, gradient ethyl acetate : hexane (15:85) to ethyl acetate). The fractions of interest were combined and the solvent removed at reduced pressure. The residue was slurried with petroleum ether (30-40 °C) and the resulting suspension collected by filtration. The collected solid was dried under reduced pressure to give Isomer D as a white
25 solid (0.93 g, 64%).

Isomer D, which is believed to have either the *2R,3S,11bR* or *2S,3R,11bS* configuration (the absolute stereochemistry was not determined), was characterized
by ¹H-NMR, ¹³C-NMR, IR, mass spectrometry, chiral HPLC and ORD. The IR, NMR and MS data for Isomer D are set out in Table 2 and the Chiral HPLC and
30 ORD data are set out in Table 4.

In Tables 1 and 2, the infra red spectra were determined using the KBr disc method. The ^1H NMR spectra were carried out on solutions in deuterated chloroform using a Varian Gemini NMR spectrometer (200 MHz). The ^{13}C NMR spectra were carried out on solutions in deuterated chloroform using a Varian Gemini NMR spectrometer (50MHz). The mass spectra were obtained using a Micromass Platform II (ES^+ conditions) spectrometer. In Tables 3 and 4, the Optical Rotatory Dispersion figures were obtained using an Optical Activity PolAAr 2001 instrument in methanol solution at 24°C . The HPLC retention time measurements were carried out using an HP1050 HPLC chromatograph with UV detection.

10 Tables 1 and 2 – Spectroscopic Data



Table 1				
Dihydrotrabenazine isomer	^1H -NMR spectrum (CDCl_3)	^{13}C -NMR spectrum (CDCl_3)	IR Spectrum (KBr solid)	Mass Spectrum (ES^+)
Isomers A and B  2S,3S,11bR OR  2R,3R,11bS	6.67 δ 1H (s); 6.57 δ 1H (s); 3.84 δ 6H (s); 3.55 δ 1H (br. d); 3.08 δ 1H (m); 2.79 δ 2H (m); 2.55 δ 3H (m); 2.17 δ 1H (m); 1.72 δ 6H (m); 1.02 δ 1H (m); 0.88 δ 6H (t)	147.7 δ ; 147.6 δ ; 130.5 δ ; 127.6 δ ; 112.1 δ ; 108.4 δ ; 70.5 δ ; 57.5 δ ; 56.3 δ ; 54.8 δ ; 53.2 δ ; 40.4 δ ; 40.1 δ ; 36.0 δ ; 28.8 δ ; 26.2 δ ; 23.7 δ ; 22.9 δ	2950 cm^{-1} ; 2928 cm^{-1} ; 2868 cm^{-1} ; 2834 cm^{-1} ; 1610 cm^{-1} ; 1511 cm^{-1} ; 1464 cm^{-1} ; 1364 cm^{-1} ; 1258 cm^{-1} ; 1223 cm^{-1} ; 1208 cm^{-1} ; 1144 cm^{-1} ; 1045 cm^{-1} ; 1006 cm^{-1} ; 870 cm^{-1} ; 785 cm^{-1} ; 764 cm^{-1}	MH^+ 320

Table 2				
Dihydrotrabenazine isomer	¹ H-NMR spectrum (CDCl ₃)	¹³ C-NMR spectrum (CDCl ₃)	IR Spectrum (KBr solid)	Mass Spectrum (ES ⁺)
<p>Isomers C and D</p> <p>2R,3S,11bR</p> <p>OR</p> <p>2S,3R,11bS</p>	<p>6.68 δ 1H (s);</p> <p>6.58 δ 1H (s);</p> <p>3.92 δ 1H (m);</p> <p>3.84 δ 6H (s);</p> <p>3.15 δ 1H (m);</p> <p>2.87 δ 3H (m);</p> <p>2.43 δ 4H (m);</p> <p>1.81 δ 1H (m);</p> <p>1.64 δ 4H (m);</p> <p>1.21 δ 1H (m);</p> <p>0.94 δ 3H (d);</p> <p>0.89 δ 3H (d)</p>	<p>147.8 δ;</p> <p>147.7 δ;</p> <p>130.4 δ;</p> <p>127.2 δ;</p> <p>112.0 δ;</p> <p>108.3 δ;</p> <p>72.4 δ;</p> <p>61.2 δ;</p> <p>58.3 δ;</p> <p>56.5 δ;</p> <p>56.3 δ;</p> <p>52.7 δ;</p> <p>38.6 δ;</p> <p>36.7 δ;</p> <p>34.4 δ;</p> <p>29.6 δ;</p> <p>26.5 δ;</p> <p>24.4 δ;</p> <p>22.5 δ</p>	<p>3370 cm⁻¹;</p> <p>2950 cm⁻¹;</p> <p>2929 cm⁻¹;</p> <p>1611 cm⁻¹;</p> <p>1512 cm⁻¹;</p> <p>1463 cm⁻¹;</p> <p>1362 cm⁻¹;</p> <p>1334 cm⁻¹;</p> <p>1259 cm⁻¹;</p> <p>1227 cm⁻¹;</p> <p>1148 cm⁻¹;</p> <p>1063 cm⁻¹;</p> <p>1024 cm⁻¹;</p> <p>855 cm⁻¹;</p> <p>766 cm⁻¹</p>	<p>MH⁺ 320</p>

Tables 3 and 4 – Chromatography and ORD Data




Table 3		
Dihydrotrabenazine isomer	Chiral HPLC Methods and Retention Times	ORD (MeOH, 21°C)
<p>Isomers A and B</p>  <p>2S,3S,11bR</p> <p>OR</p> <p>2R,3R,11bS</p>	<p>Column: Chirex (S)-VAL, (R)-NEA, 250 x 4.6 mm</p> <p>Mobile phase: Hexane : 1,2-dichloroethane : ethanol (36:62:2)</p> <p>Flow: 1.0 ml min⁻¹</p> <p>UV: 254 nm</p> <p>Retention times:</p> <p>Isomer A 16.6 min</p> <p>Isomer B 15.3 min</p>	<p>Isomer A [α_D]-114.6°</p> <p>Isomer B [α_D] +123°</p>

Table 4		
Isomers C and D	Chiral HPLC Methods and Retention Times	ORD (MeOH, 21°C)
<p>Isomers C and D</p>  <p>2R,3S,11bR</p> <p>OR</p> <p>2S,3R,11bS</p>	<p>Column: Chirex (S)-VAL, (R)-NEA, 250 x 4.6mm</p> <p>Mobile phase: Hexane : ethanol (92:8)</p> <p>Flow: 1.0 ml min⁻¹</p> <p>UV: 254 nm</p> <p>Retention times:</p> <p>Isomer C 20.3 min</p> <p>Isomer D 19.4 min</p>	<p>Isomer C [α_D] +150.9°</p> <p>Isomer D [α_D] -145.7°</p>

EXAMPLE 3Alternative Method of Preparation of Isomer B and Preparation of Mesylate Salt3A. Reduction of *RR/SS* Tetrabenazine

- 5 1M L-Selectride[®] in tetrahydrofuran (52 ml, 52 mmol, 1.1 eq) was added slowly over 30 minutes to a cooled (ice bath), stirred solution of tetrabenazine racemate (15 g, 47 mmol) in tetrahydrofuran (56 ml). After the addition was complete, the mixture was allowed to warm to room temperature and stirred for a further six hours. TLC analysis (silica, ethyl acetate) showed only very minor amounts of
- 10 starting material remained.

The mixture was poured on to a stirred mixture of crushed ice (112 g), water (56 ml) and glacial acetic acid (12.2 g). The resulting yellow solution was washed with ether (2 x 50 ml) and basified by the slow addition of solid sodium carbonate (ca. 13 g). Pet-ether (30-40 °C) (56 ml) was added to the mixture with stirring and the

15 crude β-DHTBZ was collected as a white solid by filtration.

The crude solid was dissolved in dichloromethane (ca. 150 ml) and the resulting solution washed with water (40 ml), dried using anhydrous magnesium sulphate, filtered and concentrated at reduced pressure to ca. 40 ml. A thick suspension of white solid was formed. Pet-ether (30-40 °C) (56 ml) was added and the

suspension was stirred for fifteen minutes at laboratory temperature. The product was collected by filtration and washed on the filter until snow-white using pet-ether (30-40°C) (40 to 60 ml) before air-drying at room temperature to yield β -DHTBZ (10.1 g, 67%) as a white solid. TLC analysis (silica, ethyl acetate) showed only one component.

3B. Preparation and Fractional Crystallisation of the Camphorsulphonic acid Salt of Racemic β -DHTBZ

The product of Example 3A and 1 equivalent of (*S*)-(+)-Camphor-10-sulphonic acid were dissolved with heating in the minimum amount of methanol. The resulting solution was allowed to cool and then diluted slowly with ether until formation of the resulting solid precipitation was complete. The resulting white crystalline solid was collected by filtration and washed with ether before drying.

The camphorsulphonic acid salt of (10 g) was dissolved in a mixture of hot absolute ethanol (170 ml) and methanol (30 ml). The resulting solution was stirred and allowed to cool. After two hours the precipitate formed was collected by filtration as a white crystalline solid (2.9 g). A sample of the crystalline material was shaken in a separating funnel with excess saturated aqueous sodium carbonate and dichloromethane. The organic phase was separated, dried over anhydrous magnesium sulphate, filtered and concentrated at reduced pressure. The residue was triturated using pet.-ether (30-40°C) and the organic solution concentrated once more. Chiral HPLC analysis of the salt using a Chirex (*S*)-VAL and (*R*)-NEA 250 x 4.6 mm column, and a hexane : ethanol (98:2) eluent at a flow rate of 1 ml/minute showed that the isolated β -DHTBZ was enriched in one enantiomer (e.e. ca. 80%).

The enriched camphorsulphonic acid salt (14 g) was dissolved in hot absolute ethanol (140 ml) and propan-2-ol (420 ml) was added. The resulting solution was stirred and a precipitate began to form within one minute. The mixture was allowed to cool to room temperature and stirred for one hour. The precipitate formed was collected by filtration, washed with ether and dried to give a white crystalline solid (12 g).

The crystalline material was shaken in a separating funnel with excess saturated aqueous sodium carbonate and dichloromethane. The organic phase was separated, dried over anhydrous magnesium sulphate, filtered and concentrated at reduced
5 pressure. The residue was triturated using pet.-ether (30-40°C) and the organic solution concentrated once more to yield (after drying in vacuo.) (+)- β -DHTBZ (6.6 g, ORD +107.8°). The isolated enantiomer has e.e. >97%.

3C. Preparation of Isomer B

A solution of phosphorus pentachloride (4.5 g, 21.6 mmol, 1.05 eq) in
10 dichloromethane (55 ml) was added steadily over ten minutes to a stirred, cooled (ice-water bath) solution of the product of Example 3B (6.6 g, 20.6 mmol) in dichloromethane (90 ml). When the addition was complete, the resulting yellow solution was stirred for a further ten minutes before pouring on to a rapidly stirred mixture of sodium carbonate (15 g) in water (90 ml) and crushed ice (90 g). The
15 mixture was stirred for a further 10 minutes and transferred to a separating funnel.

Once the phases had separated, the brown dichloromethane layer was removed, dried over anhydrous magnesium sulphate, filtered and concentrated at reduced pressure to give the crude alkene intermediate as brown oil (ca. 6.7 g). TLC analysis (silica, ethyl acetate) showed that no (+)- β -DHTBZ remained in the crude
20 product.

The crude alkene was taken up (dry nitrogen atmosphere) in anhydrous tetrahydrofuran (40 ml) and a solution of borane in THF (1 M solution, 2.5 eq, 52 ml) was added with stirring over fifteen minutes. The reaction mixture was then stirred at room temperature for two hours. TLC analysis (silica, ethyl acetate)
25 showed that no alkene intermediate remained in the reaction mixture.

A solution of sodium hydroxide (3.7 g) in water (10 ml) was added to the stirring reaction mixture, followed by an aqueous solution of hydrogen peroxide (50%, ca. 7 ml) and the two-phase mixture formed was stirred at reflux for one hour. TLC analysis of the organic phase at this time (silica, ethyl acetate) showed the

appearance of a product with Rf as expected for Isomer B. A characteristic non-polar component was also seen.

The reaction mixture was allowed to cool to room temperature and was poured into a separating funnel. The upper organic layer was removed and concentrated under
5 reduced pressure to remove the majority of THF. The residue was taken up in ether (stabilised (BHT), 75 ml), washed with water (40 ml), dried over anhydrous magnesium sulphate, filtered and concentrated under reduced pressure to give a pale yellow oil (8.1 g).

The yellow oil was purified using column chromatography (silica, ethyl acetate :
10 hexane (80:20), increasing to 100% ethyl acetate) and the desired column fractions collected, combined and concentrated at reduced pressure to give a pale oil which was treated with ether (stabilised, 18 ml) and concentrated at reduced pressure to give Isomer B as a pale yellow solid foam (2.2 g).

Chiral HPLC using the conditions set out in Example 3B confirmed that Isomer B
15 had been produced in an enantiomeric excess (e.e.) of greater than 97%.

The optical rotation was measured using a Bellingham Stanley ADP220 polarimeter and gave an $[\alpha_D]$ of +123.5°.

3D. Preparation of the Mesylate salt of Isomer B

The methanesulphonate salt of Isomer B was prepared by dissolving a mixture of 1
20 equivalent of Isomer B from Example 3C and 1 equivalent of methane sulphonic acid in the minimum amount of ethanol and then adding diethyl ether. The resulting white precipitate that formed was collected by filtration and dried *in vacuo* to give the mesylate salt in a yield of ca. 85% and a purity (by HPLC) of ca. 96%.

EXAMPLE 4

25 Screen for VMAT-2 binding activity using a [³H] Dihydropyridazine binding assay

Dihydropyridazine is a very potent and selective inhibitor of VMAT-2, and binds with high affinity (nM range) to this vesicular transporter. [³H] Dihydro-

tetrabenazine has been successfully used for many years as a radioligand to label VMAT-2 in human, bovine and rodent brain (e.g. Scherman *et al. J. Neurochem.* 50, 1131-1136 (1988); Near *et al. Mol. Pharmacol.* 30, 252-257 (1986); Kilbourn *et al. Eur. J. Pharmacol.* 278, 249-252 (1995); and Zucker *et al. Life Sci.* 69, 2311-5 2317 (2001)).

The four dihydrotetrabenazine isomers A, B, C and D were tested for their ability to inhibit the VMAT-2 transporter using the assay described below.

Methods and Materials

Adult rat (Wistar strain) forebrain membranes were prepared essentially as described by Chazot *et al.* (1993) *Biochem. Pharmacol.* 45, 605-610. Adult rat striatal vesicular membranes were prepared essentially as described by Roland *et al.* (2000), *JPET* 293, 329-335. 10 µg Membranes were incubated at 25°C with [³H] dihydrotetrabenazine (18-20 nM) in 50mM HEPES pH 8.0 (assay buffer), for 60 minutes, and bound radioligand was collected by rapid filtration under vacuum on 15 GF/B glass-fibre filters. Non-specific binding was determined in parallel samples in the presence of 2 µM unlabelled tetrabenazine. Radioactivity was counted in scintillation fluid in a β-counter. A full concentration range (log and half-log units) of four test compounds (Isomers A, B, C and D) were assayed (range: 10⁻¹¹ - 10⁻⁴M) in triplicate. Test compounds and tetrabenazine were dissolved in DMSO at a stock 20 concentration of 10 mM, and dilutions then prepared in assay buffer. Three independent experiments were performed for each compound. Data were analysed and curve fitted using the GraphPad Prism 3.2 package.

Results

Initially, an adult rat forebrain P₂ membrane preparation (Chazot *et al.*, 1993) was 25 prepared and was assayed as described in the original protocol. This yielded a very low level of specific binding activity.

An adult rat striatal vesicular preparation was then prepared, which yielded a significant level of stable specific [³H] Dihydrotetrabenazine binding sites (5-6

pmol/mg protein). This compares well with published data (Roland *et al.*, 2000)
This preparation was utilised for all subsequent assays.

Table 5 - Competition binding parameters for test compounds

Compound	Apparent pIC ₅₀	Overall K _I nM)	n _H
Isomer A	< 4.0 Two site fit -5.98 ± 0.33 < -4.0	< 5,900	-0.40 ± 0.08 % sites 47% 53%
Isomer B	-5.63 ± 0.05 Two-site fit -5.15 ± 0.11 -7.13 ± 0.26	139 ± 30	-0.52 ± 0.06 % sites 74% 26%
Isomer C	-6.32 ± 0.02	28 ± 2	-0.77 ± 0.07
Isomer D	-5.13 ± 0.07	440 ± 23	-0.72 ± 0.05

Data are mean ± SD for three independent experiments. K_I values were determined
5 based on a published rat striatal K_D value of 1.2 nM (Roland *et al.*, 2000).

The overall pharmacological profile in terms of overall K_I values is Isomer C >
Isomer B > Isomer D >> Isomer A.

Notably, both Isomer B and Isomer A yielded shallow competition curves, which
were best fitted to a two-site binding model.

10 Isomer A displayed a high affinity (K_I = 59 nM) and low affinity site (K_I < 5.9 μM
affinity), each contributing to approx. 50% of the total sites. This may indicate that
Isomer A can differentiate between different striatal VMAT-2 binding sites.

EXAMPLE 5

VMAT Functional Assays

A. VMAT2 Functional Assay

- Rat striatal synaptic vesicles were prepared essentially as described in Example 3. Thus, a rat striatal P₂ membrane preparation (Chazot *et al.*, 1993) was resuspended and homogenised in ice-cold distilled water. Osmolarity was restored by addition of 25 mM HEPES and 100 mM potassium tartrate (pH 7.5, 4°C). The preparation was then centrifuged for 20 minutes at 20,000 x g (4 °C). The resultant S₃ fraction was removed, magnesium sulphate was added (to give a final concentration of 1 mM, pH 7.5, 4 °C), and the mixture was centrifuged at 100,000 x g for 45 minutes. The final P₄ fraction contains the synaptic vesicles for the assay.
- 10 An aliquot of 100 µl (approx. 2.5 µg protein) of synaptic vesicles was preincubated with increasing concentrations of test compounds C and B (prepared fresh as a stock of 10⁻² M in DMSO) for 30 minutes (concentration range 10⁻⁹ M – 10⁻⁴ M), and then for 3 minutes in the assay buffer (25 mM HEPES, 100 mM potassium tartrate, 1.7 mM ascorbic acid, 0.05 mM EGTA, 0.1 mM EDTA, 2 mM ATP-Mg²⁺, pH 7.5), in the presence of [³H] dopamine (30 nM final concentration) at 30 °C.
- 15 The reaction was then terminated by addition of ice-cold buffer assay buffer pH 7.5, containing 2 mM MgSO₄ instead of 2 mM ATP-Mg²⁺, and rapid filtration achieved through Whatman filters soaked in 0.5% polyethyleneimine. The filters were washed three times with cold buffer using a Brandel Harvester. The radioactivity trapped on the filters was counted using a liquid scintillation counter and non-specific binding was determined by measuring vesicular [³H] dopamine uptake at 4 °C. The method was based on that described in Ugarte YV *et al.* (2003) *Eur. J. Pharmacol.* **472**, 165-171. Selective VMAT-2 uptake was defined using 10 µM tetrabenazine.
- 20
- 25 Both Compound C (apparent IC₅₀ = 18 ± 2 nM) and Compound B (apparent IC₅₀ = 30 ± 3 nM) inhibited [³H] dopamine uptake into rat striatal vesicles via the VMAT-2 transporter with functional affinities (profile C > B) similar to their respective binding affinities determined using the [³H] Dihydratetrabenazine binding assay.

B. VMAT1 functional assay

There are very limited native tissues which possess VMAT1 alone, in isolation from VMAT2. However, tetrabenazine displays at least a 200-fold higher affinity for VMAT2 in comparison to VMAT1, and this discrimination can be used to block the influence of VMAT2 in the functional assay (Erickson *et al.* (1996) *PNAS (USA)* **93**, 5166-5171). Adrenal chromaffin cells were isolated from young adult SD rats essentially as described in Moshharov *et al.* (2003) *J Neurosci.* **23**, 5835-5845. Thus, adrenal glands were dissected in ice cold PBS, the capsule and cortex of the glands removed and the remaining medullae were minced. After multiple washes with PBS, the tissue was incubated with Ca²⁺-free collagenase IA solution (250U/ml) for 30 minutes at 30 °C with gentle stirring. The digested tissue was rinsed three times and the dissociated cells were centrifuged at 3000 rpm to form a pellet, which was resuspended in PBS. The vesicular fraction was isolated in an identical fashion to that described for the brain preparation.

100 µl (approx. 2.5 µg protein) of synaptic vesicles were preincubated with increasing concentrations of test compound (prepared as previously described for binding assay) for 30 minutes (concentration range 10⁻⁹ M – 10⁻⁴ M). The assay was performed for 3 minutes at 30 °C in the assay buffer (25 mM HEPES, 100 mM potassium tartrate, 1.7 mM ascorbic acid, 0.05 mM EGTA, 0.1 mM EDTA, 2 mM ATP-Mg²⁺, pH 7.5), in the presence of [³H] dopamine (30 nM final concentration). [³H] dopamine uptake was measured in the presence of 10 µM tetrabenazine (selectively blocks VMAT2 at this concentration). Non-specific uptake was determined by measuring vesicular [³H] dopamine uptake at 4 °C. The reaction was then terminated by addition of ice-cold buffer assay buffer pH 7.5, containing 2 mM MgSO₄ instead of 2 mM ATP-Mg²⁺, and rapid filtration achieved through Whatman filters soaked in 0.5% polyethyleneimine. The filters were washed three times with cold buffer using a Brandel Harvester and the radioactivity trapped on the filters was counted using a liquid scintillation counter.

In the presence of 10 µM Tetrabenazine, both Compound B and Compound C poorly inhibited [³H] dopamine uptake, the IC₅₀ values being greater than 10⁻⁵M for both compounds. This indicates that both compounds have a low affinity for

VMAT-1. Moreover, the data show that both compounds have at least 2-orders of magnitude selectivity for VMAT-2 over VMAT-1.

EXAMPLE 6

Receptor and Transporter Protein Binding Studies

- 5 The four dihydrotetrabenazine isomers A, B, C and D subjected to specific binding assays to test their ability to bind to the receptors and transporter proteins described below. The results are set out in Table 6

(a) Adrenergic α_{2A} Receptor:

- Reference: S. Uhlçn *et al. J. Pharmacol. Exp. Ther.*, 271:1558-1565 (1994)
- 10 Source: Human recombinant insect Sf9 cells
- Ligand: 1 nM [³H] MK-912
- Vehicle: 1% DMSO
- Incubation time/Temp: 60 minutes @ 25 °C
- Incubation buffer: 75mM Tris-HCl, pH 7.4, 12.5mM MgCl₂, 2mM EDTA
- 15 Non Specific ligand: 10µM WB-4101
- K_d: 0.6 nM
- B_{max}: 4.6 pmole/mg protein
- Specific binding: 95%
- Quantitation method: Radioligand binding
- 20 Significance criteria: ≥ 50% of maximum stimulation or inhibition

(b) Adrenergic α_{2B} Receptor:

- Reference: S. Uhlen *et al., Eur. J. Pharmacol.*, 33 (1): 93-1-1 (1998)
- Source: Human recombinant CHO-K1 cells
- Ligand: 2.5 nM [3H] Rauwolscine
- 25 Vehicle: 1% DMSO
- Incubation time/Temp: 60 minutes @ 25 °C
- Incubation buffer: 50 mM Tris-HCl, 1 mM EDTA, 12.5mM MgCl₂, pH 7.4,
0.2% BSA at 25 °C
- Non Specific ligand: 10 µM Prazosin

K_d : 2.1 nM

B_{max} : 2.1 pmole/mg protein

Specific binding: 90%

Quantitation method: Radioligand binding

5 Significance criteria: $\geq 50\%$ of maximum stimulation or inhibition

(c) Dopamine D₁ Receptor:

Reference: Dearry *et al.*, *Nature*, 347:72-76, (1990)

Source: Human recombinant CHO cells

Ligand: 1.4 nM [3H] SCH-23390

10 Vehicle: 1% DMSO

Incubation time/Temp: 2 hours @ 37 °C

Incubation buffer: 50 mM Tris-HCl, pH 7.4, 150 nM NaCl, 1.4 nM ascorbic acid, 0.001% BSA

Non Specific ligand: 10 μ M (+)-butaclamol

15 K_d : 1.4 nM

B_{max} : 0.63 pmole/mg protein

Specific binding: 90%

Quantitation method: Radioligand binding

Significance criteria: $\geq 50\%$ of maximum stimulation or inhibition

20 **(d) Dopamine D_{2L} Receptor:**

Reference: Bunzo *et al.*, *Nature*, 336:783-787 (1988)

Source: Human recombinant CHO cells

Ligand: 0.16 nM [3H] Spiperone

Vehicle: 1% DMSO

25 Incubation time/Temp: 2 hours @ 25 °C

Incubation buffer: 50 mM Tris-HCl, pH 7.4, 150 nM NaCl, 1.4 nM ascorbic acid, 0.001% BSA

Non Specific ligand: 10 μ M Haloperidol

K_d : 0.08 nM

30 B_{max} : 0.48 pmole/mg protein

Specific binding: 85%

Quantitation method: Radioligand binding

Significance criteria: $\geq 50\%$ of maximum stimulation or inhibition

(e) Dopamine D₃ Receptor:

Reference: Sokoloff *et al.*, *Nature*, 347:146-151, (1990)

5 Source: Human recombinant CHO cells

Ligand: 0.7 nM [3H] Spiperone

Vehicle: 1% DMSO

Incubation time/Temp: 2 hours @ 37 °C

10 Incubation buffer: 50 mM Tris-HCl, pH 7.4, 150 nM NaCl, 1.4 nM ascorbic
acid, 0.001% BSA

Non Specific ligand: 25 μ M S(-)-Sulpiride

K_d: 0.36 nM

B_{max}: 1.1 pmole/mg protein

Specific binding: 85%

15 Quantitation method: Radioligand binding

Significance criteria: $\geq 50\%$ of maximum stimulation or inhibition

(f) Imidazoline I₂ (Central) Receptor:

Reference: Brown *et al.*, *Brit. J. Pharmacol.*, 99:803-809, (1990)

Source: Wistar rat cerebral cortex

20 Ligand: 2 nM [3H] Idazoxan

Vehicle: 1% DMSO

Incubation time/Temp: 30 minutes @ 25°C

Incubation buffer: 50 mM Tris-HCl, 0.5 mM EDTA, pH 7.4 at 25 °C

Non Specific ligand: 1 μ M Idazoxan

25 K_d: 4 nM

B_{max}: 0.14 pmole/mg protein

Specific binding: 85%

Quantitation method: Radioligand binding

Significance criteria: $\geq 50\%$ of maximum stimulation or inhibition

30 **(g) Sigma σ_1 Receptor:**

- Reference: Ganapathy *et al.*, *Pharmacol. Exp. Ther.*, 289:251-260, (1999)
Source: Human jurkat cells
Ligand: 8 nM [3H] Haloperidol
Vehicle: 1% DMSO
- 5 Incubation time/Temp: 4 hours @ 25 °C
Incubation buffer: 5 mM K₂HPO₄/KH₂PO₄ buffer pH 7.5
Non Specific ligand: 10 µM Haloperidol
K_d: 5.8 nM
B_{max}: 0.71 pmole/mg protein
- 10 Specific binding: 80%
Quantitation method: Radioligand binding
Significance criteria: ≥ 50% of maximum stimulation or inhibition

(h) Sigma σ_2 Receptor:

- Reference: Hashimoto *et al.*, *Eur. J. Pharmacol.*, 236:159-163, (1993)
- 15 Source: Wistar rat brain
Ligand: 3 nM [3H] Ifenprodil
Vehicle: 1% DMSO
Incubation time/Temp: 60 minutes @ 37 °C
Incubation buffer: 50 mM Tris-HCl, pH 7.4
- 20 Non Specific ligand: 10 µM Ifenprodil
K_d: 4.8 nM
B_{max}: 1.3 pmole/mg protein
Specific binding: 85%
Quantitation method: Radioligand binding
- 25 Significance criteria: ≥ 50% of maximum stimulation or inhibition

(i) Serotonin Transporter (SERT):

- Reference: Gu *et al.*, *J. Biol. Chem.*, 269(10):7124-7130, (1994)
Source: Human recombinant HEK-293 cells
Ligand: 0.15 nM [125I] RTI-55
- 30 Vehicle: 1% DMSO
Incubation time/Temp: 3 hours @ 4 °C

Incubation buffer: 100 mM NaCl, 50 mM Tris HCl, 1 μ M Leupeptin, 10 μ M PMSF, pH 7.4

Non Specific ligand: 10 μ M Imipramine

K_d : 0.17 nM

5 B_{max} : 0.41 pmole/mg protein

Specific binding: 95%

Quantitation method: Radioligand binding

Significance criteria: \geq 50% of maximum stimulation or inhibition

(j) Dopamine Transporter (DAT):

10 Reference: Giros *et al.*, *Trends Pharmacol. Sci.*, 14, 43-49 (1993)

Gu et al., *J. Biol. Chem.*, 269(10):7124-7130 (1994)

Source: Human recombinant CHO cells

Ligand: 0.15 nM [125 I] RTI-55

Vehicle: 1% DMSO

15 Incubation time/Temp: 3 hours @ 4 $^{\circ}$ C

Incubation buffer: 100 mM NaCl, 50 mM Tris HCl, 1 μ M Leupeptin, 10 μ M PMSF, pH 7.4

Non Specific ligand: 10 μ M Nomifensine

K_d : 0.58 nM

20 B_{max} : 0.047 pmole/mg protein

Specific binding: 90%

Quantitation method: Radioligand binding

Significance criteria: \geq 50% of maximum stimulation or inhibition

Table 6

Percentage Inhibition by 10 μ M Solutions of Dihydrotetrabenazine isomers of Specific Binding at Receptor and Transporter Proteins (IC ₅₀ value, where measured, is in parentheses)				
Receptor/Protein	Isomer A	Isomer B	Isomer C	Isomer D
(a) α_{2A} Receptor	86	12	13	87

Percentage Inhibition by 10 μ M Solutions of Dihydrotrabenazine isomers of Specific Binding at Receptor and Transporter Proteins (IC ₅₀ value, where measured, is in parentheses)				
Receptor/Protein	Isomer A	Isomer B	Isomer C	Isomer D
(b) α_{2B} Receptor	44	14	-7	50
(c) D ₁ Receptor	78	1	6	38
(d) D _{2L} Receptor	87	16	-14	58
(e) D ₃ Receptor	69	7	9	63
(f) I ₂ Receptor	74	8	0	55
(g) σ_1 Receptor	48	82	59	82
(h) σ_2 Receptor	64	64	61	69
(i) SERT	19	86 (0.35)	77 (2.75)	8
(j) DAT	3	4	-2	2

EXAMPLE 7Enzyme Assays

Isomers B and C were tested for their ability to inhibit enzymes involved in the processing of monoamines in the CNS, namely Catechol O-Methyl Transferase (COMT), Monoamine Oxidase A and Monoamine Oxidase B. The assay methods used are described below and the results are set out in Table 7.

(a) Catechol O-Methyl Transferase (COMT) Inhibition

Source: Porcine liver

10 Substrate: 3 mM catechol + S-adenosyl-L-[³H]methionine

Vehicle: 1% DMSO

Pre-incubation time/Temp: None

Incubation time: 60 minutes @ 37 °C

Incubation buffer: 100 mM potassium phosphate, 10mM MgCl₂, 3 mM DTT
containing 12 units/ml adenosine deaminase, pH 7.4

Quantitation method: Quantitation of [³H] guaiacol.

Significance criteria: ≥ 50% of maximum stimulation or inhibition

5 **(b) Monoamine Oxidase MAO-A Inhibition**

Source: Human recombinant

Substrate: 50 μM kynuramine

Vehicle: 1% DMSO

Pre-incubation time/Temp: 15 minutes @ 37 °C

10 Incubation time: 60 minutes @ 37 °C

Incubation buffer: 100 mM KH₂PO₄, pH 7.4

Quantitation method: Spectrofluorimetric quantitation of 4-hydroxyquinoline

Significance criteria: ≥ 50% of maximum stimulation or inhibition

(c) Monoamine Oxidase MAO-B Inhibition

15 Source: Human recombinant

Substrate: 50 μM kynuramine

Vehicle: 1% DMSO

Pre-incubation time/Temp: 15 minutes @ 37 °C

Incubation time: 60 minutes @ 37 °C

20 Incubation buffer: 100 mM KH₂PO₄, pH 7.4

Quantitation method: Spectrofluorimetric quantitation of 4-hydroxyquinoline

Significance criteria: ≥ 50% of maximum stimulation or inhibition

Table 7

Percentage Inhibition of Enzyme Activity by 10 μM Solutions of Dihydrotetrabenazine isomers				
Enzyme	Isomer A	Isomer B	Isomer C	Isomer D
(a) COMT		-12	-22	
(b) MAO-A		3	3	

Percentage Inhibition of Enzyme Activity by 10 μ M Solutions of Dihydropyridazinone isomers				
Enzyme	Isomer A	Isomer B	Isomer C	Isomer D
(c) MAO-B		-5	-5	

EXAMPLE 8Cellular Assays

The ability of isomers B and C to inhibit uptake of serotonin (5-hydroxytryptamine) by human embryonic kidney cells was measured using the following assay conditions:

Target:	Human HEK-293 cells
Vehicle:	0.4 % DMSO
Incubation Time/Temp:	10 minutes @ 25 °C
10 Incubation buffer:	5mM Tris-HCl, 7.5 mM HEPES, 120 mM NaCl, 5.4 mM KCl, 1.2 mM CaCl ₂ , 1.2 mM MgSO ₄ , 5 mM glucose, 1 mM ascorbic acid, pH 7.1
Quantitation Method:	Quantitation of [³ H] serotonin uptake
15 Significance criteria:	≥ 50% inhibition of [³ H] serotonin uptake relative to fluxetine response.

Results

Compound B was shown to be an antagonist and produced 56 % inhibition of serotonin uptake at a concentration of 10 μ M. Compound B had an IC₅₀ of 7.53 μ M.

20 Compound C was also shown to be an antagonist and produced 86 % inhibition of serotonin uptake at a concentration of 10 μ M. Compound B had an IC₅₀ of 1.29 μ M.

EXAMPLE 95-HT_{1D/1B} Binding Assay

The ability of Compound B and Compound C to bind to 5-HT_{1D/1B} receptors was tested using an assay based on the one described by Millan, MJ *et al.* (2002) *Pharmacol. Biochem. Behav.* 71, 589-598. [N-methyl ³H] GR-125743 was used as the radioligand for both 5-HT_{1D} and 5-HT_{1B} receptors. Adult SD rat forebrain P₂ membranes (Chazot *et al.*, 1993) were used for the assay. The assay buffer used was 50 mM Tris-HCl pH 7.7 at room temperature containing 4 mM calcium chloride, 0.1% ascorbic acid and 10 μM pargyline. 5-HT (10 μM) was used to define non-specific binding. Incubation with 1 nM [³H] GR-125743 was carried out for 1 hour at room temperature, and the reaction was terminated by rapid filtration using a Brandel Harvester through GF/B filters pre-soaked in 0.1% polyethyleneimine, followed by three washes with ice-cold buffer (supplemented with 0.1% BSA). A dose range of 10⁻¹⁰-10⁻⁴M was utilised. The resultant competition curves were analysed using the GraphPad Prism 4 package.

Both compounds B and C displayed poor displacement of [³H] [N-methyl] GR-125743 binding to rat forebrain membranes (IC₅₀ values > 10⁻⁴M), suggesting that both B and C have a low affinity for 5-HT_{1D/1B} receptors.

EXAMPLE 10

Determination Of The Intestinal Permeability of Dihydratetabenazine Isomers A, B, C and D using The Caco-2 Absorption Assay

The Caco-2 absorption assay is a well-established system for the *in vitro* estimation of *in vivo* intestinal absorption of drugs – see Meunier *et al.*, *Cell Biology and Toxicology*, 11:187-194, Wils *et al.*, *Cell Biology and Toxicology*, 10:393-397, and Gres *et al.*, *Pharm Sci*, 15(5):726-732.

The assay relies on the ability of Caco-2 cells to differentiate into enterocytes when cultured on a microporous filter for a period of approximately 21 days. During the culture period, the Caco-2 cells undergo spontaneous morphological and biochemical changes, which produce a polarized monolayer with a well-defined brush border on the apical surface, as well as tight cellular junctions. Therefore, these cells may be used as an *in vitro* model for the analysis of drug permeability.

Absorption across the Caco-2 monolayer can be measured in two directions: apical-to-basolateral or basolateral-to-apical, by adding the compound to the apical or the basolateral chamber, respectively. At various time-points, samples are collected from the receiver-chamber for analysis for the rate of absorption as measured by the apparent permeability coefficient (P_{app}) across the monolayer.

The P_{app} value reflects a combination of the test article permeability through both transcellular (through cell membranes) and the paracellular (across the tight junctions between the cells) pathways. The relative contribution of these pathways depends upon the pKa, partition coefficient (log D), molecular radius, and charge of the test article at a given pH. P_{app} values can then be used to rank-order compounds for their permeability through Caco-2 monolayers.

The apparent permeability coefficients (P_{app}) of the four dihydrotetrabenazine isomers A, B, C and D at 50 μ M were determined using the Caco-2 absorption model and ranked in relation to reference compounds of low, medium and high permeability. The radio-labelled reference standards mannitol (low), salicylic acid (medium) and testosterone (high) were used to establish a rank order of permeability. The P_{app} value of each dihydrotetrabenazine test article was estimated by measuring its concentration in the donor and receiver compartments after 1 hour. Absorption was determined at pH 7.4 across cell monolayers in the apical-to-basolateral direction. Caco-2 cells used to estimate P_{app} values were grown for 26 days on Transwell inserts in 12-well plates. Monolayer integrity was verified before and after the absorption assay by the methods of transepithelial electrical resistance ($\text{Ohm}\cdot\text{cm}^2$) and Lucifer Yellow.

Materials and Methods

Stock solutions of mannitol, salicylic acid and testosterone were prepared in methanol at 50 mM. On the day of the assay, the reference standards were diluted in Hank's balanced salt solution (HBSS), pH 7.4 to a final concentration of 50 μ M. Radio-labelled ^{14}C -mannitol, ^3H -testosterone and ^{14}C -salicylic acid were then added to their corresponding un-labelled media to have a final specific activity of 0.35 - 0.65 $\mu\text{Ci}/\text{mL}$. Dihydrotetrabenazine isomer samples were prepared at a

concentration of 50 mM in DMSO. Each stock solution was further diluted in HBSS buffer (pH 7.4) to a final working concentration of 50 μ M

The Caco-2 cell suspensions were prepared as follows. One vial of Caco-2 initial cell ID No. Caco-29-080299 from passage number 29 (American Type Culture Collection (VA, USA) was thawed and put in culture in a 150 cm² flask containing Caco-2 culture medium. At confluency, the culture medium was removed and cells were washed with 5 ml of PBS. Cells were detached following the addition and incubation with 0.25 % trypsin-EDTA (2.0 ml per flask) for approximately 10 minutes at 37 °C. Detachment of cells was monitored under a microscope and stopped by the addition of 10 mL of Caco-2 culture medium. Cell viability and concentration were assessed by the trypan blue exclusion method. Once the cell density and viability were determined, Caco-2 cells were diluted in culture medium to a final working concentration of 2.0×10^5 cells/ml. The Caco-2 culture medium contained Dulbecco's Modified Eagle Medium, 10% fetal bovine serum, 100 μ M non-essential amino acids, 100 U/ml penicillin and 100 μ g/ml streptomycin.

Costar polycarbonate membranes (0.4 μ m pore size) were pre-equilibrated with Caco-2 culture medium for 1 hour in a 37 °C water-jacketed incubator with 5% CO₂. The content of the apical chamber was removed and replaced with 500 μ l of Caco-2 cell suspension (200 000 cells/ml). Cells were further maintained in culture for 26 days in a 37 °C water-jacketed incubator with 5% CO₂.

Prior to the assay, all monolayers were washed twice with HBSS and their transepithelial electrical resistance (TEER) was measured with a Millicell-ERS meter. TEER values obtained in the absence of cells were subtracted as background signal. Only monolayer with TEER values over 150 Ohm-cm² were used for the absorption assay experiment.

All absorption experiments were conducted in triplicate at pH 7.4. The rate of absorption of each reference standard and dihydrotetrabenazine test article was assessed in the apical-to-basolateral direction. Aliquots (100 μ l) of each working solution (reference standards and test articles at 50 μ M) were set aside at the beginning of the assay for the determination of the initial concentration (C₀).

Absorption experiments were initiated by replacing the content of the donor chamber with 500 μ l of Hanks Balanced Salt Solution containing test articles or reference compounds. Cells were returned to the CO₂ incubator for the absorption assay. Samples of 100 μ l were collected from the receiver and donor chambers after
5 1 hour and were used to determine the percentage of recovery. Radio-labelled reference standards, mannitol, salicylic acid and testosterone were used as quality controls and for the comparative ranking of dihydrotetrabenazine test articles.

At the end of the absorption experiment, the integrity of each cell monolayer was assessed by monitoring the leakage of Lucifer Yellow from the apical-to-basolateral
10 side. All solutions were removed from the apical and basolateral chambers. The basolateral chambers were replenished with 1.5 ml of fresh HBSS, while the apical chambers were filled with 0.5 ml of 120 μ g/ml Lucifer Yellow solution. Cells were returned to the incubator for a period of 1 hour, after which samples of 100 μ l were collected and quantified spectrophotometrically with the SpectraMax 340PC-plate
15 reader at 428 nm.

A volume of 20 μ l of each radio-labelled sample was added to 10 ml of scintillation cocktail (ScintiSafe 30%) and counted for up to 5 minutes with a liquid scintillation analyzer (1900CA Tri-Carb).

Caco-2 cell incubations were analyzed for the presence of dihydrotetrabenazine
20 using a liquid chromatography-tandem/mass spectrometry (LC-MS/MS) method.

The apparent permeability coefficients were calculated using the equation $P_{app} = dQ/dt \times 1/A \times 1/C_0$ (cm/sec) in which dQ/dt is the rate of diffusion of compound (μ g/sec or integration area/sec), A is the total cell membrane surface area (cm^2) and C_0 is the initial concentration (μ g/mL or integration area/sec).

25 The apical-to-basolateral P_{app} values of the different dihydrotetrabenazine test articles were compared with the P_{app} values determined for the reference standards. The results are shown in table 8. Compounds C, D and A of dihydrotetrabenazine have a respective P_{app} value of 21.14×10^{-6} , 24.87×10^{-6} and 25.52×10^{-6} cm/sec, which is comparable to the testosterone reference standard.

Compound B has a P_{app} value of 11.98×10^{-6} cm/sec, which is similar to the salicylic acid reference standard.

Table 8

Compound Name	Direction	TEER (Ohm-cm ²)	Lucifer Yellow (%/hr)	Recovery (%)	1-hr P_{app} (cm/sec) $\times 10^{-6}$
Mannitol	A-to-B	379 \pm 8	BLQ	97.1 \pm 0.3	1.18 \pm 0.14
Salicylic Acid	A-to-B	407 \pm 22	1.02	91.5 \pm 11.4	8.91 \pm 8.14
Testosterone	A-to-B	401 \pm 26	0.28	105.0 \pm 10.6	29.10 \pm 7.05
Compound B	A-to-B	367 \pm 15	BLQ	90.1 \pm 6.5	11.98 \pm 5.26
Compound C	A-to-B	390 \pm 14	BLQ	101.5 \pm 12.4	21.14 \pm 8.65
Compound D	A-to-B	414 \pm 54	BLQ	106.5 \pm 23.8	24.87 \pm 14.76
Compound A	A-to-B	409 \pm 68	BLQ	106.8 \pm 7.9	25.52 \pm 5.92

Compounds C, D and A have a P_{app} value close to the testosterone value, indicating that these compounds have high permeability in the caco-2 model whereas Compound B has a P_{app} value between the salicylic acid and testosterone values, indicating that it has a medium permeability in the Caco-2 model. These results suggest that the four dihydrotetrabenazine isomers should be highly absorbed through the intestinal epithelium *in vivo*.

10 EXAMPLE 11

Comparison of the Sedative Properties of Tetrabenazine and the Dihydrotetrabenazine Isomers B and C

A study was carried out in rats to determine whether the dihydrotetrabenazine isomers of the invention have sedative properties. The effects of the isomers on

spontaneous locomotor activity in rats were compared with the effects produced by tetrabenazine and haloperidol using the methods set out below.

Methods

Male Sprague-Dawley rats, (Charles River Laboratories, Saint-Germain/L'Arbresle, France), weighing 200-250 g at the beginning of the study, were used for the studies. The rats were housed, 2 or 3 per cage, in Makrolon type III cages, in a room set up with the following environmental conditions: temperature: 20 ± 2 °C, humidity : minimum 45 %, air changes: > 12 per hour, light/dark cycle of 12 h/12 h [on at 7:00 a.m.]. The rats were allowed to acclimatize to their conditions for at least five days before commencement of the study. The rats received food (Dietex, Vigny, France, ref. 811002) and water (tap water in water bottle) *ad libitum*.

Solutions of each test compound in corn oil were freshly prepared on the day of the experiment. Haloperidol was prepared in hydroxyethylcellulose, 0.5% in deionized water. Either the vehicle or the test compounds were administered as a single dose (0.3, 1, 3 and 10 mg/kg, 2 mL/kg i.p.). The reference compound haloperidol (1 mg/kg) was administered i.p. (2 mL/kg).

The animals were placed in plexiglass cages under a video camera in a room with low light intensity (maximum 50 lux). At forty five minutes and 3 hours after administration, locomotor activity was determined during 20 minute periods using a video image analyzer (Videotrack, View Point, France). Locomotor activity was recorded in the reference group (haloperidol) at 1 hour after administration. The number and duration of ambulatory movements and duration of inactivity was measured. At the end of the locomotor activity measurement (45 minutes and 3 hours), palpebral closure and arousal were be scored as follows in the plexiglass cage :

Palpebral closure :

0 : (normal) eyelids wide open

1 : eyelids slightly drooping

2 : ptosis, drooping eyelids approximately half-way

3 : eyelids completely shut

Arousal :

- 1 : very low, stupor, coma, little or no responsiveness
- 2 : low, some stupor, « dulled », some head or body movement
- 3 : somewhat low, slight stupor, some exploratory movements with
5 periods of immobility
- 4 : normal, alert, exploratory movements /slow freeze
- 5 : somewhat high, slight excitement, tense, sudden darting or
freezing
- 6 : very high, hyper alert, excited, sudden bouts of running or body
10 movements

The number of occurrences and duration (in seconds) of ambulatory (large) movements and the duration of periods of inactivity (seconds) was determined during two 20 minute periods (45 minutes and 3 hours after administration) using a video image analyzer (Videotrack, ViewPoint, Lyon, France). Image tracking was
15 performed using a video camera placed above the plexiglass cage, recording overall locomotor activity. Images recorded with the video camera were digitalized and displacement of the centre of gravity of the digital image spots was tracked and analyzed using the following method: the speed of displacement of the centre of gravity of the spot was measured and two threshold values were set to define the
20 type of movement : threshold 1 (high speed) and threshold 2 (low speed). When the animal moved and the speed of displacement of the centre of gravity of the spot was above threshold 1, the movement was considered as an ambulatory movement. When the animal remained inactive, the speed was below threshold 2, the movement was considered as inactivity.

25 The results were expressed as the means \pm SEMs of the 12 individual values. Statistical analyses were carried out using ANOVA (one way) and Dunnett's t-test and with the non parametric test of Kruskal-Wallis followed by a Mann & Whitney U-test for the sedation cotation. A p value of $p < 0.05$ was taken as indicating significance..

30 Protocol

- Group size n=12
- Group 1: Reference, haloperidol (1 mg/kg i.p.)
- Group 2: Vehicle control group (2 ml/kg i.p.)
- Group 3: tetrabenazine (0.3 mg/kg i.p.)
- 5 Group 4: tetrabenazine (1 mg/kg i.p.)
- Group 5: tetrabenazine (3 mg/kg i.p.)
- Group 6: tetrabenazine (10 mg/kg i.p.)
- Group 7: Isomer C (0.3 mg/kg i.p.)
- Group 8: Isomer C (1 mg/kg i.p.)
- 10 Group 9: Isomer C (3 mg/kg i.p.)
- Group 10: Isomer C (10 mg/kg i.p.)
- Group 11: Isomer B (0.3 mg/kg i.p.)
- Group 12: Isomer B (1 mg/kg i.p.)
- Group 13: Isomer B (3 mg/kg i.p.)
- 15 Group 14: Isomer B (10 mg/kg i.p.)

Results

Effects of Tetrabenazine, Isomer B, Isomer C (0.3, 1, 3 and 10 mg/kg i.p.) on spontaneous locomotor activity in rats				
Observation time : 45 minutes after administration				
		Large movements		Inactivity
Treatment	Dose (mg/kg)	Occurrence	Duration (sec)	Duration (sec)
Vehicle	2 mL/kg	286 ± 35	76.4 ± 10.9	349.0 ± 37.4
Haloperidol	1 mg/kg	58 ± 33 **	14.8 ± 8.5 **	637.2 ± 60.1 **
Tetrabenazine	0.3 mg/kg	253 ± 32	66.8 ± 10.7	390.4 ± 37.4
Tetrabenazine	1 mg/kg	189 ± 32	46.5 ± 8.6	456.5 ± 50.5
Tetrabenazine	3 mg/kg	38 ± 25 **	8.7 ± 5.9 **	697.8 ± 39.7 **
Tetrabenazine	10 mg/kg	1 ± 1 **	0.2 ± 0.2 **	723.1 ± 46.5 **
Isomer C	0.3 mg/kg	285 ± 34	79.2 ± 10.0	323.7 ± 25.6

Isomer C	1 mg/kg	295 ± 30	71.8 ± 8.3	324.6 ± 38.1
Isomer C	3 mg/kg	308 ± 36	84.0 ± 9.4	322.7 ± 27.8
Isomer C	10 mg/kg	254 ± 32	66.5 ± 9.9	368.7 ± 30.9
Isomer B	0.3 mg/kg	268 ± 36	72.0 ± 9.6	346.1 ± 36.9
Isomer B	1 mg/kg	297 ± 22	87.0 ± 7.6	334.0 ± 23.2
Isomer B	3 mg/kg	313 ± 38	89.1 ± 12.4	342.2 ± 33.3
Isomer B	10 mg/kg	298 ± 37	84.0 ± 11.2	333.1 ± 26.9
Observation time : 3 hours after administration				
		Large movements		Inactivity
Treatment	Dose (mg/kg)	Occurrence	Duration (sec)	Duration (sec)
Vehicle	2 mL/kg	101 ± 23	24.8 ± 6.0	540.9 ± 37.5
Haloperidol	1 mg/kg	9 ± 8 **	2.2 ± 2.0 **	723.6 ± 50.2 **
Tetrabenazine	0.3 mg/kg	96 ± 14	24.3 ± 4.2	545.9 ± 37.1
Tetrabenazine	1 mg/kg	90 ± 16	21.5 ± 4.0	556.9 ± 31.1
Tetrabenazine	3 mg/kg	9 ± 4 **	1.7 ± 0.9 **	729.9 ± 26.8 **
Tetrabenazine	10 mg/kg	3 ± 1 **	0.6 ± 0.3 **	762.1 ± 40.7 **
Isomer C	0.3 mg/kg	113 ± 19	31.4 ± 6.0	519.3 ± 33.7
Isomer C	1 mg/kg	128 ± 24	30.3 ± 6.5	510.2 ± 44.9
Isomer C	3 mg/kg	125 ± 22	30.2 ± 5.5	493.6 ± 38.5
Isomer C	10 mg/kg	164 ± 30	42.7 ± 8.0	465.7 ± 49.0
Isomer B	0.3 mg/kg	101 ± 29	28.9 ± 9.2	566.4 ± 44.3
Isomer B	1 mg/kg	125 ± 18	34.5 ± 6.2	525.8 ± 28.6
Isomer B	3 mg/kg	113 ± 17	31.1 ± 6.5	530.5 ± 38.0
Isomer B	10 mg/kg	120 ± 26	30.9 ± 6.4	515.0 ± 53.0

**Significantly different from Vehicle group (p,0.01)ANOVA one way followed by Dunnett's test.

The results demonstrate that tetrabenazine produces a dose-dependent sedative effect 45 minutes and 3 hours after administration whereas Isomer B and Isomer C show no sedative effects at any time, although isomer C does show a slight and
5 non-significant hyperlocomotor effect 3 hours after administration. .

EXAMPLE 12

Pharmaceutical Compositions

(i) Tablet Formulation -I

A tablet composition containing a dihydrotetrabenazine of the invention is prepared
10 by mixing 50mg of the dihydrotetrabenazine with 197mg of lactose (BP) as diluent, and 3mg magnesium stearate as a lubricant and compressing to form a tablet in known manner.

(ii) Tablet Formulation - II

A tablet composition containing a dihydrotetrabenazine of the invention is prepared
15 by mixing the compound (25 mg) with iron oxide, lactose, magnesium stearate, starch maize white and talc, and compressing to form a tablet in known manner.

(iii) Capsule Formulation


A capsule formulation is prepared by mixing 100mg of a dihydrotetrabenazine of the invention with 100mg lactose and filling the resulting mixture into standard
20 opaque hard gelatin capsules.

Equivalentents

It will readily be apparent that numerous modifications and alterations may be made to the specific embodiments of the invention described above without departing from the principles underlying the invention. All such modifications and alterations
25 are intended to be embraced by this application.


CLAIMS

1. 3,11b-*cis*-dihydrotetrabenazine.
2. 3,11b-*cis*-dihydrotetrabenazine in substantially pure form, for example at an isomeric purity of greater than 90%, typically greater than 95% and more preferably greater than 98%.
3. 3,11b-*cis*-dihydrotetrabenazine according to claim 1 or claim 2 which is in a (+)-isomeric form.
4. A composition comprising 3,11b-*cis*-dihydrotetrabenazine substantially free of 3,11b-*trans*-dihydrotetrabenazine.
5. A composition comprising 3,11b-*cis*-dihydrotetrabenazine and containing less than 5% of 3,11b-*trans*-dihydrotetrabenazine, preferably less than 3% of 3,11b-*trans*-dihydrotetrabenazine, and more preferably less than 1% of 3,11b-*trans*-dihydrotetrabenazine.
6. A composition according to claim 4 or claim 5 wherein the 3,11b-*cis*-dihydrotetrabenazine is a (+)-isomer.
7. The 2*S*,3*S*,11*bR* isomer of 3,11b-*cis*-dihydrotetrabenazine having the formula (Ia):




8. The 2*R*,3*R*,11*bS* isomer of 3,11b-*cis*-dihydrotetrabenazine having the formula (Ib):


63



9. The *2R,3S,11bR* isomer of 3,11b-*cis*-dihydro-tetrabenazine having the formula (Ic):



- 5 10. The *2S,3R,11bS* isomer of 3,11b-*cis*-dihydro-tetrabenazine having the formula (Id):




11. A 3,11b-*cis*-dihydro-tetrabenazine isomer having an ORD $[\alpha_D]$ value of -114.6° when measured in methanol at 21°C .
- 10 12. A 3,11b-*cis*-dihydro-tetrabenazine isomer having an ORD $[\alpha_D]$ value of approximately $+123^\circ$ when measured in methanol at 21°C .
13. A 3,11b-*cis*-dihydro-tetrabenazine isomer having an ORD $[\alpha_D]$ value of $+150.9^\circ$ when measured in methanol at 21°C .
14. A 3,11b-*cis*-dihydro-tetrabenazine isomer having an ORD $[\alpha_D]$ value of -145.7° when measured in methanol at 21°C .
- 15

15. A dihydrotetrabenazine isomer having the spectroscopic characteristics set out in Table 1 herein and the chromatographic and optionally the ORD characteristics set out in Table 3 herein.
16. A dihydrotetrabenazine isomer having the spectroscopic characteristics set out in Table 2 herein and the chromatographic and optionally the ORD characteristics set out in Table 4 herein.
17. Dihydrotetrabenazine isomer A having the spectroscopic characteristics set out in Table 1 herein, the chromatographic characteristics set out in Table 3 herein, and having laevorotatory optical activity.
18. Dihydrotetrabenazine isomer B having the spectroscopic characteristics set out in Table 1 herein, the chromatographic characteristics set out in Table 3 herein, and having dextrorotatory optical activity.
19. Dihydrotetrabenazine isomer C having the spectroscopic characteristics set out in Table 2 herein, the chromatographic characteristics set out in Table 4 herein, and having dextrorotatory optical activity.
20. Dihydrotetrabenazine isomer D having the spectroscopic characteristics set out in Table 2 herein, the chromatographic characteristics set out in Table 4 herein, and having laevorotatory optical activity.
21. A dihydrotetrabenazine as defined in any one of the preceding claims in the form of a free base.
22. A dihydrotetrabenazine as defined in any one of claims 1 to 20 in the form of an acid addition salt.
23. A dihydrotetrabenazine according to claim 22 wherein the salt is a methane sulphonate salt.
24. A dihydrotetrabenazine as defined in any one of the preceding claims for use in medicine or therapy, for example in the treatment of hyperkinetic movement disorders such as Huntington's disease, hemiballismus, senile


chorea, tic, tardive dyskinesia and Tourette's syndrome, or the treatment of depression.

25. A pharmaceutical composition comprising a dihydrotetrabenazine as defined in any one of claims 1 to 23 and a pharmaceutically acceptable carrier.
26. The use of a dihydrotetrabenazine as defined in any one of claims 1 to 23 for the manufacture of a medicament for the treatment of hyperkinetic movement disorders such as Huntington's disease, hemiballismus, senile chorea, tic, tardive dyskinesia and Tourette's syndrome, or the treatment of depression.
27. A method for the prophylaxis or treatment of a hyperkinetic movement disorder such as Huntington's disease, hemiballismus, senile chorea, tic, tardive dyskinesia and Tourette's syndrome, or the treatment of depression, in a patient in need of such prophylaxis or treatment, which method comprises the administration of an effective prophylactic or therapeutic amount of a dihydrotetrabenazine as defined in any one of claims 1 to 23.
28. A process for preparing a dihydrotetrabenazine as defined in any one of claims 1 to 23, which process comprises the reaction of a compound of the formula (II):




with a reagent or reagents suitable for hydrating the 2,3-double bond in the compound of formula (II) and thereafter where required separating and isolating a desired dihydrotetrabenazine isomer form .

29. A process for preparing a dihydrotetrabenazine as defined in any one of claims 1 to 23, which process comprises subjecting a compound of the formula (III):




to conditions for ring-opening the 2,3-epoxide group in the compound of the formula (III), and thereafter where required separating and isolating a desired dihydrotetrabenazine isomer form.

- 5 30. A process for preparing a compound of the formula (III) as defined in claim 29 which process comprises reacting an alkene compound of the formula (II) as defined in claim 27 with an oxidising agent (such as a peroxy acid) suitable for forming an epoxide group.
- 10 31. A process for preparing a compound of the formula (II) as defined in claim 28 which process comprises dehydrating a 3,11-*trans*-dihydrotetrabenazine with a dehydrating agent such as a phosphorus halide or phosphorus oxyhalide.
32. A compound of the formula (II):



- 15 33. A compound of the formula (III):



34. A Mosher's acid ester of a compound as defined in any one of claims 1 to 23.

INTERNATIONAL SEARCH REPORT

PCT/GB2005/000464

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D455/06 A61K31/473 A61P25/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	M. R. KILBOURN ET AL: "Absolute Configuration of (+)-alpha-Dihydrotetrabenazine, an Active Metabolite of Tetrabenazine" CHIRALITY, vol. 9, no. 1, 1997, pages 59-62, XP002329921 cited in the application page 59, left-hand column; page 60, Figure 1 <div style="text-align: center;">----- -/--</div>	1-21,24

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

- 31 May 2005

Date of mailing of the international search report

10/06/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Hass, C

INTERNATIONAL SEARCH REPORT

PCT/GB2005/000464

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>M. KILBOURN ET AL: "Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific" EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 278, no. 3, 1995, pages 249-252, XP002329922 cited in the application pages 249 to 250, "Introduction"; page 250, Figure 1</p>	1-21,24
A	<p>A. BROSSI ET AL: "Syntheseversuche in der Emetin-Reihe. 3. 2-Hydroxy-hydrobenzo'a!chinolizine" HELVETICA CHIMICA ACTA, vol. 41, 1958, pages 1793-1806, XP008047475 BASEL, CH cited in the application page 1794, compound VIa; page 1795, reaction scheme; page 1797, paragraph "Resultate der pharmakologischen Prüfung"</p>	1-21,24
A	<p>US 6 087 376 A (CROOKS ET AL) 11 July 2000 (2000-07-11) column 3, line 21 - line 49 column 5, line 59 - line 67 figure 7</p>	1,24
A	<p>US 2 843 591 A (A. BROSSI ET AL) 15 July 1958 (1958-07-15) cited in the application claims 1-3,5</p>	1,25
A	<p>US 2 830 993 A (A. BROSSI ET AL) 15 April 1958 (1958-04-15) cited in the application the whole document</p>	1

INTERNATIONAL SEARCH REPORT

PCT/GB2005/000464

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 27 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

PCT/GB2005/000464

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
US 6087376	A	11-07-2000	US 5830904 A	03-11-1998
US 2843591	A		NONE	
US 2830993	A		NONE	